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ABSTRACT
Thirty four million people are infected with HIV, the causative agent of acquired 
immunodeficiency syndrome (AIDS), which has caused an estimated 25 million deaths in 
the three decades since the virus was identified. Dramatic progress has been made in 
understanding the viral lifecycle, enabling the development of safe and effective 
antiretroviral therapies that greatly reduce AIDS-associated mortality.
Viral entry is mediated by the viral glycoprotein, Env. Env, composed of gp120 
and gp41 subunits, adopts a transient conformation known as the prehairpin intermediate 
during fusion that is vulnerable to inhibition by peptides that bind the gp41 N-trimer 
region. Our lab has developed D-peptide inhibitors that bind to the N-trimer and prevent 
viral entry.
The HIV lifecycle, current therapeutics, and emerging fields of HIV prevention 
and treatment are described in Chapter 1. Chapter 2 describes the discovery of highly 
potent D-peptide inhibitors of entry that bind to the N-trimer region and inhibit viral 
entry. These peptides, optimized by structure-guided mirror-image phage display, inhibit 
viral entry with nM potency. Trimerization of D-peptide inhibitors yields significant 
further improvement in potency due to avidity, and inhibit a broad panel of primary 
isolates. D-peptides are insensitive to proteolysis, a significant advantage over L-peptide 
inhibitors of entry.
Chapter 3 describes the optimization of the trimer scaffold and conjugation to 
potency and pharmacokinetic enhancing cargoes. These cargoes dramatically improve 
potency through localization to the membrane surface. Chapter 4 examines the 
pharmacokinetics of D-peptide HIV entry inhibitors and strategies employed to increase 
circulating half-life in an effort to prolong dosing intervals and develop an inhibitor 
suitable for clinical application. Peptidomimetics, including D-peptides, as well as 
display technologies and advances in non-natural peptide design, are reviewed in Chapter 
5. The final chapter describes future directions for D-peptide inhibitors of HIV entry and 
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CHAPTER 1
INTRODUCTION TO HIV AND HIV INHIBITORS
The HIV Pandemic
HIV, the causative agent of AIDS, infects an estimated 34 million people 
worldwide, and since its identification nearly three decades ago has caused an estimated
25 million deaths. In 2010, 2.7 million new cases of HIV were contracted, and 1.8 
million people died of AIDS-related illness worldwide (UNAIDS World Report, 2011). 
Since the identification of HIV, dramatic progress has been made in understanding the 
viral lifecycle, enabling the development of numerous HIV antiretroviral therapeutics, 
which have dramatically reduced AIDS-associated mortality. Globally, the rate of AIDS- 
related deaths are in decline due to the increasing availability of effective antiretroviral 
therapy, though many new cases are reported each year. HIV is a global pandemic, but 
sub-Saharan Africa remains the most affected, accounting for 68% of infections 
worldwide and 70% of new infections in 2010, despite only accounting for 12% of the 
global population. This situation is likely the result of a combination of factors, including 
low condom use, insufficient screening and subsequent medical support, and a lack of 
affordable treatments to reduce mortality. This problem highlights the need for the
development of a highly potent, broadly effective and affordable agent for the treatment 
and prevention of HIV.
The fight against HIV/AIDS has been dramatically altered by the introduction of 
highly active antiretroviral therapy (HAART). HAART, a multidrug cocktail, can 
suppress viral load to undetectable levels (<50 copies/ml), preserve or reconstitute the 
immune system, and prolong life1-4. Though viral load in patients on HAART therapy 
often drops below the limit of detection, cessation of therapy results in viral rebound as 
latent viral reservoirs withstand HAART 5^ , necessitating life-long treatment.
HIV
HIV is an enveloped retrovirus, with a single-stranded, positive-sense RNA 
genome, belonging to the lentivirus genus. HIV is a dual-tropic virus, infecting either 
CD4+/CCR5+ or CD4+/CXCR4+ cells. HIV infection results in the progressive 
depletion of CD4+ T-cells and the eventual loss of humoral immunity, leading to the 
development of acquired immunodeficiency syndrome (AIDS), which is marked by a 
dramatic increase in susceptibility to opportunistic infections and ultimately death if 
untreated 7^ .
Additionally, HIV infected individuals successfully treated with antiretroviral 
therapy remain at a dramatically higher risk for a number of non-AIDS related diseases, 
such as cancers9, community-acquired pneumonia10, cognitive impairment11,12, 
osteoporosis13, and cardiovascular disease14,15, reducing life span at least 10 years when 
compared to the general population16,17. Despite viral suppression by antiretroviral 
therapy, HIV infected individuals experience persistent inflammation and immune
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activation, and this abnormality correlates strongly with the incidence of non-AIDS 
related diseases18.
The mechanism behind persistent immune activation is believed to be two-fold. 
First, HIV replication in gut-associated lymphoid tissue (GALT) causes a weakening of 
the mucosal barrier, allowing microbial translocation and subsequent systemic immune 
activation19,20. Second, the depletion of Th17 cells, which reduce microbial 
translocation21-23, further weakens the barrier against microbial influx. Taken together, 
the result is significant microbial translocation as evidenced by elevated levels of a 
number of markers, including lipopolysaccharide, bacterial 16S ribosomal DNA levels, 
and soluble CD14, inducing systemic T-cell activation24,25. The subsequent chronic 
inflammatory state is believed to contribute significantly to the development of non­




Viral entry into host cells is mediated by the viral envelope (Env) glycoprotein. 
Env is translated as a single polypeptide (gp160), then cleaved by a cellular protease into 
the non-covalently associated gp120 and gp41 subunits that assemble into trimeric spikes 
embedded in the viral membrane. gp41 mediates membrane fusion and consists of 
several structural elements: an ectodomain composed of two heptad repeat regions (HR1 
and HR2, or N-peptide and C-peptide, respectively) that bridge the viral and host cell 
membranes, a N-terminal hydrophobic sequence known as the fusion peptide that
3
penetrates the host cell membrane, a transmembrane helix domain that anchors the 
protein to the viral membrane, and a C-terminal cytoplasmic tail that interacts with the 
interior of the virus. Cellular interactions are mediated by gp120 through association 
with the primary cell receptor (CD4) and chemokine co-receptor (either CXCR4 or CCR5 
depending on viral tropism). This interaction induces conformational changes in gp120 
that propagate to gp41 and lead to membrane fusion.
Biochemical and structural data on gp41 suggest an HIV fusion mechanism with 
significant similarity to other viral glycoprotein-mediated fusion mechanisms (e.g., HA- 
mediated influenza entry)27. In this model, cleavage of gp160 into gp41 and gp120 places 
gp41 in a metastable state27. Upon interaction with cellular receptors, a conformational 
change in gp120 allows structural rearrangement of gp41 into an elongated state. This 
rearrangement extends gp41 toward the target cell and embeds the fusion peptide in the 
host cell membrane27. This “spring-loaded” mechanism converts the metastable pre­
fusion gp41 state to the elongated fusion intermediate state, known as the pre-hairpin 
intermediate. Collapse of the pre-hairpin intermediate is driven by packing of C-peptides 
against the central N-peptide trimeric coiled coil in an antiparallel fashion, which draws 
the viral and host cell membranes into close proximity, leading to membrane fusion 
(Figure 1-1). The N-peptide and C-peptide are thought to be exposed for different 
periods of time during fusion28,29, but the exact changes in Env conformation upon 
receptor and coreceptor engagement remain unclear.
A complete gp41 structure has yet to be solved, though using biochemical data 
paired with protein dissection, the critical components involved in gp41 function were 
identified and a core structure was obtained. Crystal structures of the gp41 core reveal
4
5Figure 1-1. Model of HIV Fusion. Upon receptor and coreceptor engagement by 
gp120, a conformational change in gp120 allows gp41 to extend into the pre-hairpin 
intermediate, embedding the fusion peptide in the cell membrane and tethering the virus 
to the host cell. In a slow reaction (on the order of minutes), gp41 undergoes a 
conformation collapse into the six-helix bundle, with C-peptides folding back to pack in 
the grooves of N-trimer in an antiparallel fashion. This trimer-of-hairpins juxtaposes the 
viral and host membranes and drives membrane fusion. Addition of exogenous C- 
peptide inhibits fusion in a dominant negative manner. D-peptides bind to the pocket 
region of N-trimer, preventing six-helix bundle formation and membrane fusion. 
Adapted from 30.
similarities to other well-characterized viral envelope proteins and provide key insight 
into the mechanism of viral membrane fusion. The gp41 core consists of a six-helix 
bundle in which three N-helices form a central trimeric coiled coil (N-trimer) and three 
C-peptide helices pack in an antiparallel manner into the grooves formed between N- 
helices 31,32. This structure represents the postfusion state after collapse of the prehairpin 
intermediate. The N-trimer follows the canonical coiled coil arrangement, with 
interactions between helices at the a and d heptad repeat positions in a “knobs into holes” 
architecture in which B-branched residues of one helix pack into neighboring helices. 
The groove into which C-peptides pack is formed primarily by the residues at positions e 
and g, which are predominantly hydrophobic. The high level of conservation in N- 
peptide residues among both HIV and SIV strains can be explained by the selection 
pressure on positions a and d required for coiled-coil interactions, and positions e and g 
for C-peptide interactions. The a and d positions of the C-peptide largely mediate 
interactions with the central coiled coil, the majority of which are hydrophobic. The less- 
conserved C-helix outer face is formed by positions b, c, and f  and contains several polar 
residues, making the C-helix amphipathic.
Though much of the entry process has been deduced, several critical questions 
remain unanswered. Cryo-EM analysis of the native Env trimer provides low resolution 
information about the conformation of the native Env spike33, but the detailed 
conformational changes upon receptor and coreceptor interaction remain unclear34-37. It 
is unknown how many envelope trimers are required to drive membrane fusion, with 
estimates ranging from one38 to eight39. Cryo-EM of fusing virions reveals multiple 
trimers forming a ring around the interface between the virus and host cell (the “entry
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claw”)40, though it is unknown if all of these spikes are functional and required for 
fusion, or if they simply stabilize the virion-cell interaction.
Fusion and Uncoating 
Upon successful completion of viral entry, the viral core is released into the 
cytoplasm for the subsequent step of uncoating. As the viral core dissociates, the viral 
RNA genome is reverse transcribed by the viral reverse transcriptase (RT). RT converts 
the single-stranded positive-sense RNA genome into double-stranded DNA using RNA- 
dependent DNA polymerase, DNA-dependent DNA polymerase, and RNase-H activities. 
Once viral DNA synthesis is complete and a double stranded genome has been 
synthesized, the viral pre-integration complex is formed. The pre-integration complex 
(PIC) is composed of the viral proteins Vpr, MA (matrix), NC (nucleocapsid) and IN 
(integrase), as well as several host proteins in addition to the dsDNA genome. The PIC is 
able to cross the nuclear envelope, allowing integration into nondividing cells. Once in 
the nucleus, integrase mediates the integration of the viral genome into the host genome 
via a strand transfer reaction. Cellular machinery transcribes the integrated viral genome 
into viral genomic and messenger RNA.
Assembly, Budding and Maturation 
Env is synthesized as a polyprotein precursor (gp160) on the rough endoplasmic 
reticulum41. As translation of gp160 proceeds, it is modified with N- and O-linked 
oligosaccharides and oligomerizes into trimers. Trimeric Env is then trafficked to the 
Golgi, where furin proteases cleave gp160 into surface gp120 and transmembrane gp41
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subunits, which remain non-covalently associated. Env is then trafficked to the plasma 
membrane and enriched at lipid rafts, sites of increased cholesterol and sphingolipid 
content41-43.
Once at the plasma membrane, only a small portion of the Env is successfully 
incorporated into virions, due to endocytosis and shedding of gp12041,44,45. The gp41 
cytoplasmic tail (CT) plays a critical role in Env incorporation, surface expression, and 
stability (gp120/gp41 interaction)41. CT also targets Env to lipid rafts due to 
palmitylation within this region46. Drug resistance mutations are often accompanied by a 
reduction in Env incorporation, and the relationship between resistance and Env 
incorporation is discussed in Chapter 6.
Assembly of the HIV virion is driven by the viral polyprotein Gag, composed of 
the MA (matrix), CA (capsid), NC (nucleocapsid), and p6 domains. The N-terminal MA 
domain directs Gag to the plasma membrane (PM) via specific interactions between the 
N-terminal myristoyl group and the PM phosphoinositide PI(4,5)P247, while CA homo- 
oligomerizes to form ordered Gag assemblies. NC binds RNA, and is critical for 
packaging of the viral genome. The C-terminal domain, p6, interacts with components of 
the host cell ESCRT pathway, which mediates budding of the virion from the cell 
membrane48. A pseudoknot present in the gag-pol reading frame causes generation of the 
Gag-Pol polyprotein in a small percentage of reads through a frameshift, which is 
required for the synthesis of the Pol protein49.
Virion genesis begins with oligomerization of Gag at the inner leaflet of the 
plasma membrane, inducing outward curvature of the membrane and forming a round 
bud encapsulating the viral genome. Scission from the membrane requires recruitment of
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the host endosomal sorting complex required for transport (ESCRT) pathway48, mediated 
by the Gag p6 domain. The p6 P(T/S)AP motif recruits ESCRT-1 via interactions with 
the TSG101 subunit while a second YP(X)nL motif recruits the host protein ALIX50. 
ESCRT-I functions as an adaptor to recruit ESCRT-III, in conjunction with ALIX50. 
ALIX further recruits CHMP4/ESCRT-III proteins through an N-terminal Bro domain, 
inducing CHMP4 filament assembly at the scission neck. The AAA-ATPase VPS4, 
recruited by ESCRT-III, disassembles the CHMP4 filament, leading to constriction of the 
membrane neck and ultimately leading to membrane scission47,50,51. After membrane 
scission and particle release, the viral protease cleaves Gag, leading to maturation of the 
particle, a process marked by the formation of a fullerene CA cone and a reduction in the 
stiffness of the virus52.
HIV Inhibitors 
Reverse Transcriptase 
Reverse transcriptase inhibitors, composed of the subclasses nucleoside reverse 
transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors 
(NNRTI’s) act upon viral RT, halting the synthesis of DNA from the RNA genome and 
synthesis of the second DNA strand. NRTIs (e.g., tenofovir) lack the critical 3’-hydroxyl 
group on their sugar moiety, allowing integration into the growing nucleotide chain but 
preventing subsequent chain elongation formation of the 3’-5’-phosphodiester bond 
between the incorporated NRTI and the incoming 5’-nucleoside triphosphate53. Though 
effective, reverse transcriptase can escape inhibition by removing the newly added NRTI 
(pyrophosphorolysis)54-56 and by selecting natural nucleoside substrates over the NRTI53.
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NNRTI’s (e.g., nevirapine) bind near the nucleotide binding site, inducing a 
conformational change that alters the binding site and reduces enzyme activity57,58. 
Resistance to NNRTIs arises from mutations at the binding site that reduce inhibitor 
affinity59.
Integrase
Integrase, the viral protein responsible for integrating the viral genome into the 
host genome through 3’ end processing and strand transfer, is the target of FDA-approved 
raltegravir and late-stage clinical candidate elvitegravir. Both compounds target the 
strand transfer reaction through binding to the integrase/DNA complex and interacting 
with two essential magnesium ion cofactors in the active site. Mutation of the residues 
that coordinate the two magnesium ions are responsible for raltegravir resistance, though 
at a cost of overall viral fitness60.
Protease
Cleavage of viral Gag and Gag-Pol polyproteins is mediated by HIV protease, and 
is required for viral infectivity61. Ten small molecule inhibitors of protease are in clinical 
use (e.g., atazanavir, darunavir), all of which interact with the substrate binding site to 
prevent proteolysis. Resistance to protease illustrates HIV’s sophisticated ability to 
escape inhibition, with resistance normally occurring through a multistep process in 
which initial mutations at the active site reduce inhibitor efficacy as well as protease 
function, with significant cost to viral fitness. Subsequent compensatory mutations repair 
enzyme function (and thus viral fitness), and finally mutations arise in the polyprotein 
substrates that restore substrate processing53. Such plasticity illustrates the significant
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challenge of resistance in the treatment of HIV, and the need for multi-drug therapy that 
targets multiple viral targets.
Entry Inhibitors
Viral entry begins with interaction between gp120 and the cellular receptor CD4. 
Soluble CD4 (sCD4) can compete with surface CD4 to bind gp120, and in some strains 
prematurely activates gp41, leading to its rapid inactivation62. However, sCD4 potency 
against primary strains is poor63, sCD4 is rapidly cleared from circulation64, and at 
suboptimal doses infectivity is increased, presumably by “priming” Env for coreceptor 
binding65,66. In contrast, the small molecule inhibitors BMS-378806 and BMS-488043 
inhibit the interaction between gp120 and CD4 through interaction with the CD4 binding 
region of gp120 via a poorly understood mechanism that may either compete with CD4 
binding or prevent conformational changes in gp120 upon CD4 binding37,67. In a phase II 
clinical trial, BMS-378806 suffered from rapid resistance and development was 
discontinued68, though it is efficacious as a microbicide in animal models69. BMS-488043 
is a more potent inhibitor currently in clinical development, but also suffers from the 
rapid development of resistance70.
Coreceptor Inhibitors
Chemokine receptors (CCR5 and CXCR4, depending on viral tropism) are 
required for viral entry in addition to the primary CD4 receptor. Observations of high-risk 
populations revealed certain individuals with CCR5 deletions were highly resistant to
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HIV infection71. Several chemokine antagonists have been developed, though only one, 
maraviroc (Selzentry), has reached market to date.
Maraviroc binds to CCR5, preventing binding of the CCR5 ligands CCL3 and 
CCL5 (RANTES) and blocking subsequent CCR5-signaling events without having any 
CCR5 agonist activity itself or inducing CCR5 internalization68,72. When utilized in 
combination therapy for treatment-experienced patients with poor viral control (>5000 
copies HIV RNA/ml), 47% of patients receiving maraviroc twice daily achieved viral 
loads <50 copies/ml when compared to 16% of controls receiving combination therapy 
with a placebo73. Unfortunately, Maraviroc is only effective in patients with exclusively 
CCR5-tropic viruses, and requires a costly and time-consuming tropism test prior to 
administration, which has limited its use. Resistance to maraviroc is primarily mediated 
by mutations in gp120 that allow usage of the drug-bound coreceptor rather than tropism 
switching74, though a significant number of patients fail maraviroc because of the 
presence of previously undetected CXCR4 virus that expands upon therapy75.
One of the natural ligands of CCR5, RANTES, functions to prevent gp120 
coreceptor engagement by competing with gp120 binding and inducing CCR5 
internalization76. However, the agonistic effects of RANTES-induced internalization of 
CCR5 (including leukocyte recruitment and activation of natural killer cells) lead to pro- 
inflammatory side effects that can enhance infection. For these reasons, RANTES 
analogues that do not agonize CCR5, including AOP-RANTES, NNY-RANTES, and 
PSC-RANTES, have been developed77,78. These inhibitors bind to CCR5 without 
inducing internalization, instead functioning as competitive antagonists of gp120. PSC- 
RANTES is in microbicide development, and has been shown to prevent infection in a
12
macaque vaginal challenge model79,80, as have the related compounds 6P4-RANTES and 
5P12-RANTES81.
Blocking the CXCR4-gp120 interaction has been pursued using both small 
molecules and polypeptide mimics of CXCR4 ligands. AMD3100, a small molecule 
antagonist of CXCR4, is a potent inhibitor of CXCR4-tropic virus in vitro, though 
clinical development as an HIV entry inhibitor was discontinued due to lack of in vivo 
suppression of viral load in addition to cardiac toxicity82. Polypeptide mimics of the 
natural CXCR4 ligand (CXCL-12) that act by binding to CXCR4 and preventing gp120 
engagement have been developed, though these have not succeeded clinically due to
limited load suppression in vivo83-86.
Anti-Env Antibodies
Several epitopes from Env can generate neutralizing antibodies against HIV: the 
CD4 binding site of gp120 (b12), the gp41 prehairpin intermediate (D5), glycans on 
gp120 (2G12), the gp120 V3 loop (447-52D), the V1/V2 loop (PG9 and PG16), and the 
membrane-proximal external (MPER) region of gp41 (2F5 and 4E10).
The CD4 binding site on gp120 is deeply recessed, making recognition of this 
conserved region difficult in the context of intact surface envelope. However, b12 has 
solved this problem by having an extended finger-like complementarity-determining 
region 3 (CDRH3) that is able to reach deeply into gp120 and block CD4 binding87,88.
During the fusion process, gp41 is exposed and vulnerable to inhibition by 
peptides that bind the N-trimer (see below). Synthetic peptides derived from the N-trimer 
region were used as targets and panned against phage libraries expressing single-chain
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variable region fragments. From this library the D5 scFV was identified. D5 binds to the 
pocket region of gp41 (see below), and inhibited 9/19 strains tested with high-nM/low-
89|iM potency .
The antibody 2G12, which targets gp120 through binding a number of surface 
glycans, is able to suppress viral load and prevent viral infection in a humanized mouse 
model (Rag2"/"yc"/") at concentrations of 5-25 |ig/ml and 100 |ig/ml, respectively90. 2G12 
is of special interest because the IgG dimer exhibits a unique VH domain swap, 
generating a binding interface composed of two heavy domains in proximity. The result 
is a multivalent binding surface composed of the VH-VH binding site in addition to the
87 91 92two canonical VL-VH binding sites ’ ’ . 2G12’s ability to bind glycans is very 
surprising given that it could cause auto-reactivity, but is tolerated because recognition is 
defined by the spacing of the glycans, and is specific for gp12087,93. 447-52D targets a 
stable region of the hypervariable V3 loop of gp120, interacting with several conserved 
residues as well as main chain atoms in the flanking regions to prevent coreceptor 
engagement94. However, many primary strains avoid neutralizing antibodies to the V3 
loop by reducing accessibility of this region, making these antibodies ineffective87.
Despite an extremely high level of sequence variability and a high level of N- 
glycosylation in the V1/V2 loop, the antibodies PG9 and PG16 bind to this region and 
inhibit 80% of HIV-1 isolates examined95. The crystal structure of PG9 in complex with 
V1/V2 reveals interactions with strand C of V1/V2 and 5 of 7 saccharides of the glycan at 
residue 156 or 17396.
2F5 and 4E10 both target the conserved and relatively accessible membrane- 
proximal external region (MPER) of gp41. Attempts to generate neutralizing antibodies
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with peptides from the shared 2F5 and 4E10 epitope have failed, suggesting that these 
antibodies target an epitope that is dependent on structural context, proximity to the 
membrane surface, or includes the membrane itself87. 2F5/2G1297, and 2F5/4E10/2G1298 
were able to suppress viral load transiently or delay viral rebound after cessation of 
antiretroviral therapy when given systemically, though only 2G12 appeared to be active, 
in part due to the significantly longer half life of 2G12 when compared to 2F5 and 4E10. 
Autoreactivity with cardiolipin for both 2F5 and 4E10 has been reported99, raising 
concern for use of these antibodies.
Challenges in Env Antigen Design
Success at eliciting neutralizing antibodies to HIV-1 by immunization has to date 
been limited, due to heavy glycosylation of gp120, and an effective steric defense of 
gp41100. Using C-peptide inhibitors conjugated to cargoes of varying sizes, it was shown 
that gp120 shields the gp41 N-trimer region from immune surveilance101. Recently, a 
vaccine trial in Thailand utilizing a pox vaccine composed of Gag, Pol, Nef, and 
membrane-anchored gp120 reported modest success in preventing infection (31%)102, 
though vaccinated individuals who later became infected did not show decreased viral 
loads or T-cell depletion.
Peptide Inhibitors of HIV Entry
Early attempts to inhibit viral entry using peptides were based on predictions that 
regions of gp41 would assume an extended amphipathic a-helix similar to those found in 
other fusogenic viruses such as influenza. A peptide derived from a putative coiled coil
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domain (N-trimer), DP107, inhibited viral entry with low micromolar potency, and was 
theorized to act through a dominant negative mechanism103,104. Later work on other 
predicted amphipathic helices yielded DP178, taken from the C-peptide region, which 
inhibited entry with low-nM potency105. DP178 (also known as T-20) is a 36-amino acid 
peptide that was ultimately approved as the first HIV entry inhibitor, enfuvirtide (brand 
name: Fuzeon).
Enfuvirtide inhibits viral entry with nM potency and in clinical trials reduces viral 
load by 2 logs106. Despite its effectiveness, enfuvirtide was only approved as a salvage 
therapy for patients harboring multidrug-resistant virus and is rarely used. Enfuvirtide, 
like all unstructured L-peptides, suffers from rapid proteolytic degradation by proteases 
present in all tissues, necessitating very high dosing (90 mg injections twice daily) to 
achieve sustained inhibitory concentrations. This large dosage paired with formulation 
issues (high pH to achieve solubility) led to injection site reactions in many patients. 
Enfuvirtide’s complex synthesis and large dosing requirement (~70 g/year/patient) results 
in a very high cost of ~$30,000/year/patient, which is prohibitively expensive for 
application in most of the world. Moreover, because enfuvirtide binds to the groove 
region of N-trimer, but not the highly conserved pocket region (see below), it is
107 108susceptible to the rapid emergence of resistance . Though enfuvirtide had limited 
clinical impact, it provided validation that entry inhibition through binding to N-trimer 
was an achievable route to reduce viral load and prolong life.
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The N-trimer Pocket
As described above, the interaction between C-helices and the N-trimer is 
predominantly mediated by interactions between the hydrophobic face of C-peptides and 
the hydrophobic grooves of the N-trimer. Within this binding interface lies a deep 
hydrophobic pocket near the C-terminus of the N-trimer with a volume of ~400 A3 that 
accepts three critical C-peptide residues (Trp628, Trp631, and Ile635)105,109-112. Several 
N-peptide residues that form this pocket (Leu568 and Trp571) are critical for membrane 
fusion, and mutations that alter the pocket architecture or chemical composition greatly 
reduce fusion activity105,109-112. Due to the critical role the pocket plays in 6-helix bundle 
formation and the very high level of conservation in this region, it was identified as a 
promising target for entry inhibitors113-115.
The pocket contributes a significant amount of binding energy to the interaction 
between N- and C-peptides in the six-helix bundle structure, and mutations within this 
region are poorly tolerated, as compensatory mutations in the companion C-peptide 
region are required to restore binding energy to functional levels. Indeed, the importance 
of the pocket is highlighted by the ability of a C-peptide containing the pocket binding 
region (T-1249) to inhibit virus resistant to C-peptide lacking the pocket binding region 
(enfuvirtide)108,116-120. More recently, it has been shown that T-1249 retains clinical 
efficacy in patients failing enfuvirtide, highlighting the importance of pocket binding121. 
Additionally, RNA encoding the pocket also encodes a structured RNA region of the 
Rev-responsive element (RRE) that is required for nuclear export of viral RNA, thereby 
providing pressure to maintain pocket conservation at the nucleotide level.
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D-Peptide Inhibitors of Entry
D-peptides are chemically identical to natural L-peptides, except in chirality at the 
Ca and side chain chiral centers. D-peptides retain the excellent characteristics of peptide 
therapeutics (very high specificity and affinity) while overcoming the primary limitation 
of L-peptides (proteolytic degradation). Proteases are chiral-specific and cleave only L- 
substrates, making D-peptides proteolytically insensitive. This property affords the 
possibility for a significantly longer circulating half-life and therefore lower dosing.
In the development of D-peptides that bind to the pocket region, a soluble trimeric 
pocket mimic was utilized in mirror image phage display to select high affinity binding 
sequences from a randomized peptide library (see Chapter 5 for a detailed discussion of 
mirror-image phage display and other screening techniques). The resulting sequences 
bind the pocket with high affinity and selectivity and inhibit viral entry by preventing 
formation of the six-helix bundle.
A broad panel of phage libraries were utilized in the initial panning process in 
order to survey multiple potential solutions to pocket binding, including disulfide- 
constrained libraries of 4, 7, 8, and 10 residues as well as linear libraries of 6, 7, 8, 10, 12, 
and 15 residues. Pocket-specific binding was only observed in the disulfide constrained 
10-mer library. A consensus sequence CXXXXXEWXWLC was observed in the 9 
identified pocket-binding phage clones. This sequence resembles the C-peptide pocket- 
binding WXXWI motif. These early generation D-peptide inhibitors exhibited modest 
potency in HIV infectivity assays (11-270 |iM against a lab-adapted isolate), but 
importantly provided proof-of-concept that D-peptides could prevent entry through 
binding the N-trimer pocket122.
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Due to limitations in developing a library that completely covers the possible 
sequence space defined by 10 randomized residues, the first generation D-peptide library 
(~3.6 x 108 sequences) contained less than one in a million of all possible
122,123sequences . Given that the possible sequence space was not exhaustively examined, 
it was extremely likely that further panning would yield peptides with tighter binding 
affinities. Residues that were highly selected in early rounds were fixed, and a second 
library was generated with greater depth of coverage in variable residues. Among the 
sequences discovered in the follow-up panning of this constrained 10-mer library was the 
8-mer peptide PIE1 (Peptide Inhibitor of Entry, CESPEWRWLC), likely arising from a 
rare replication error. Despite the very low prevalence of the 8-mer in the initial library, 
this sequence was among the most prevalent winning sequences, suggesting that the 8- 
mer library offered a better binding solution than the 10-mer. Indeed, a crystal structure 
of the 8-mer sequence in complex with the pocket mimic IQN17 revealed that the more 
compact core enforced by the shorter peptide sequence excluded water molecules present 
in the 10-mer core, and the shorter disulfide loop may also reduce the entropic penalty on 
binding123. Subsequent optimization of the 8-mer core sequence led to the discovery of 
PIE7, which inhibits entry with mid-nM potency (620 nM, HXB2 strain)123.
Crystal structures of PIE7 in complex with IQN17 reveal that residues outside the 
cysteines (flanking residues) make significant contacts with the pocket. Optimization of 
these residues through further mirror-image phage display resulted in the discovery of 
PIE12, which is ~40-fold more potent than PIE7 against the difficult to inhibit strain 
JRFL124. For further discussion of the discovery and optimization of D-peptides, see 
Chapters 2 and 5.
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D-peptide inhibitors of entry target the pocket region of N-trimer, with each N- 
trimer presenting three symmetry-related pockets. Multimerization of D-peptide
30 , 123,124inhibitors dramatically improves potency through avidity (see Chapters 2 and 3).
As the affinity of multimeric D-peptide inhibitors of entry improved, we observed a 
“potency plateau” beyond which further gains in binding affinity no longer led to 
improvements in antiviral potency123,124. This plateau is presumably the result of the 
limited time window available for inhibitor binding, as D-peptides target the transient 
pre-hairpin intermediate29. Binding affinity reflects both on-rate and off-rate of the 
inhibitor, with faster on-rates and slower off-rates leading to improvements in affinity. 
The off-rate of trimeric D-peptides is longer than the lifetime of the pre-hairpin 
intermediate, making the on-rate the limiting factor. However, the on-rate for our 
inhibitors is near the diffusion-limited rate, establishing a potency limit based on kinetics 
of inhibitor association rather than the off-rate of the inhibitor124. Localization to the site 
of viral entry could overcome this plateau, and indeed inhibitors that tether the compound 
to the membrane surface through cholesterol conjugation dramatically improve 
potency30,125 (see Chapter 3).
Despite the existence of the “potency plateau”, we continued to improve the 
binding affinity of our D-peptide inhibitors, theorizing that the available binding energy 
retained by inhibitors within the plateau could improve their capacity to absorb the 
impact of resistance mutations. This “resistance capacitor” functions by utilizing the 
available binding energy to eliminate the growth advantage conferred to viruses 
harboring mutations that reduce the binding affinity, preventing the step-wise 
accumulation of subtle resistance mutations (see Figure 1-2). To examine the power of
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Figure 1-2. The Potency Plateau. A hypothetical plot of antiviral potency (y-axis) 
against binding affinity (x-axis). For monomeric and dimeric inhibitors, binding affinity 
and potency correlate, with improvements in binding affinity leading to improvements in 
antiviral potency. Trimeric inhibitors are in the potency plateau, in which the antiviral 
potency is limited by the temporal availability of the prehairpin intermediate target. In 
the event of a mutation conferring a 100-fold loss in binding affinity, monomeric and 
dimeric inhibitors exhibit a correlated loss in potency. However, trimeric inhibitors 
retain comparable potency due to the presence of excess binding energy, eliminating the 
selective advantage of the resistance mutation and preventing the step-wise accumulation 
of subtle resistance mutations.
the resistance capacitor, passaging studies in sub-lethal doses of inhibitor revealed high- 
level PIE12-trimer resistance after 65 weeks124, significantly longer than the 3 weeks 
required to develop resistance to enfuvirtide.
Peptide Pharmacokinetics
Peptide therapeutics are able to bind with very high affinity and specificity, and 
offer the ability to disrupt large protein-protein interactions, which are typically 
considered “undruggable” by traditional small molecules. However, peptides are rapidly 
proteolytically degraded and cleared via renal filtration. D-peptides avoid proteolysis, 
but are still susceptible to pharmacokinetic challenges due to their small molecular 
weight. To overcome this, we have examined several strategies to slow renal clearance 
and improve circulating half-life, including conjugation to large molecular weight 
polyethylene glycol (PEG), cholesterol, fatty acids and acyl chains. Large molecular 
weight PEG increases the mass of the compound, with the apparent size being larger than 
expected due to extensive hydration of PEG. In Chapter 4, we explore conjugation of 
PIE12 and PIE12-trimer to cholesterol, fatty acids, and acyl chains to optimize potency 
(via membrane localization) and slow clearance (via membrane and/or albumin binding).
Prophylactic HIV Treatment 
Preexposure prophylaxis (PrEP) and postexposure prophylaxis (PEP) are the 
administration of antiretrovirals before and after exposure to HIV, respectively, to 
prevent the establishment of HIV infection. PrEP therapy includes systemic treatment
22
such as oral nevirapine to prevent mother-to-child transmission and 
tenofovir/emtricitabine (Truvada).
Preexposure Prophylaxis
An effective pre-exposure prophylactic agent is desperately needed to reduce the 
transmission rate of HIV. Prevention methods including monogamy, safe-sex practices 
and condom use have proven effective in preventing the transmission of HIV. However, 
in many parts of the world women are at risk for infection due to a lack of social power to 
enforce such methods due to social, religious, or socioeconomic factors. PrEP and 
microbicides (see below) offer the potential to empower women to protect themselves 
from infection with a discreet prophylactic agent, such as a vaginal ring or orally dosed 
PrEP.
Systemic PrEP has shown effectiveness in preventing infection in animal 
models126, and orally delivered PrEP agents show great promise in reducing 
transmission127. One such compound, Truvada, composed of emtricitabine (FTC) and 
tenofovir (TDF), was recently approved as a once-daily oral PrEP agent. Truvada was 
shown to dramatically reduce HIV transmission in men who have sex with men128, and 
several ongoing studies confirm the efficacy of TDF/TDF-FTC in heterosexual men and
129 130 131women . The Partners in PrEP trial examined PrEP amongst serodiscordant 
couples where the infected partner is not utilizing antiretroviral therapy, with TDF and 
TDF-FTC reducing infection rates 62% and 73%, respectively132, comparable to the 
results observed in the ongoing TDF2 trial.
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Systemic treatment with antiretrovirals suppresses viral load both systemically as 
well as in genital secretions, providing an avenue to reduce transmission rate between 
serodiscordant couples. An ongoing study (HPTN-052) examining the effect of 
antiretroviral therapy for the infected partner observed a 96% reduction in transmission 
when therapy was initiated prior to CD4+ T-cell depletion and the onset of HIV-1-related 
symptoms133. These data provide strong evidence that ART treatment can dramatically 
reduce transmission to and from infected individuals.
Oral PrEP agents must effectively reach the site of infection, which limits the 
effectiveness of some categories of HIV inhibitors, such as protease inhibitors, which fail 
to achieve significant concentrations within vaginal and rectal tissue134. However, many 
agents are able to achieve inhibitory concentrations in these tissues, such as NRTIs,
135,136 137maraviroc , , and raltegravir , and therefore show promise as PrEP agents.
Successful PrEP strategies must overcome two important obstacles; cost and 
adherence. Particularly in resource-poor nations, the financial burden of preventative 
treatment must be low to reach a broad patient audience. The current market cost for 
many effective antiretrovirals exceeds the financial resources of those most in need. As 
clinical trials have shown, patient adherence is critical for effectiveness, with 
dramatically improved efficacy when patient compliance is high. Developing a daily or 
intermittent PrEP agent that is easy to implement with minimal side effects is essential 
for effectiveness, and will likely define the success of future PrEP efforts.
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Microbicides
Microbicides are products designed to be applied topically to the vagina or 
rectum to prevent infection. Recent studies suggest that a majority of HIV infections
138,139begin with a single virus or a small number of viruses , and that initial infection is 
slow to spread from local tissues140-142. Given that the mucosa provides a strong barrier 
to infection itself, with the infection rate estimated at 0.11% (per coital act) for 
monogamous couples143, the addition of topical HIV inhibitors could further reduce the 
likelihood of infection and provide an excellent avenue for prophylaxis. It is estimated 
that in a three-year period in 73 lower-income countries, a microbicide with 60% efficacy 
per coital act used by 20% of women in half of all sex acts without a condom could 
prevent up to 2.5 million infections144. In addition, microbicides are advantageous 
because they are applied locally, allowing for a much higher concentration at the site of 
infection with decreased likelihood of systemic side effects and greatly reduced cost.
Early microbicide attempts primarily focused on non-specific inhibitors to prevent 
viral entry, such as detergents, spermicides, and polyanionic gels145. These agents had 
limited efficacy and alarmingly could increase infectivity due to disruption of the 
mucosal barrier and subsequent inflammation and recruitment of HIV target cells, as was 
observed with Nonoxinol-9146. One of the first applications of a specific inhibitor, the 
antibody b12 showed efficacy against vaginal challenge in non-human primates at a 
concentration of 1 mg/ml (5 ml total)147. Though effective, the production cost of b12 
makes microbicide application impractical, but this study provides proof of concept that 
local inhibitor application is a feasible strategy to prevent infection. The environment of 
the vaginal and rectal mucosa is protease-rich, making application of peptide and protein
25
inhibitors a significant challenge. This highlights one of the advantages of D-peptide 
inhibitors of entry (such as PIE12-trimer), which are protease resistant. Indeed, PIE12- 
trimer was able to prevent infection in humanized mice vaginally challenged with HIV- 
1148, and future work will examine if protease insensitivity allows for lower and less 
frequent dosing.
Recent clinical trials have raised hopes of using approved HIV therapeutics as 
microbicides. The CAPRISA 004 trial showed that 1% tenofovir gel as a vaginal 
microbicide reduced HIV transmission by up to 53% in high-compliance patients149. A 
subsequent trial, VOICE, is examining both 1% tenofovir vaginally applied gel, oral 
tenofovir, and oral emtricitabine-tenofovir (FTC/TDF, Truvada)150. Both the oral 
tenofovir and tenofovir gel arms failed to reduce the transmission of HIV for unknown 
reasons and were discontinued151, though poor patient compliance appears to be a 
contributory factor 152. The FACTS 001 trial is replicating the regimen utilized in the 
CAPRISA 004 trial to further examine 1% tenofovir vaginal gel for efficacy as a 
microbicide.
Rectal transmission is significantly higher than vaginal transmission, highlighting 
the need for a rectal microbicide. Tenofovir gel has also shown efficacy in rectal 
microbicide models, providing protection from SIV in rhesus macaques153. The gel has 
been reformulated for rectal use after gastrointestinal side effects were reported in the 
RMP-02/MTN-006 trial, with significant improvement in the follow-up MTN-007 trial. 
An upcoming trial (MTN-017) will expand upon the number of patients enrolled, and 
compare the results to oral Truvada to determine the efficacy of tenofovir gel as a rectal 
microbicide.
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Compounds from a number of drug classes have been examined for efficacy in 
microbicide applications. The entry inhibitor BMS-378806 was shown to prevent SHIV 
vaginal challenge in nonhuman primates69, with the more potent derivative BMS-793 
currently in preclinical development as a microbicide. Maraviroc, a CCR5 inhibitor, was 
shown to protect against vaginal SHIV challenge154 in a macaque model as well as HIV-1 
vaginal challenge in a humanized mouse model155. Raltegravir, a clinically approved 
integrase inhibitor, has been shown to be effective against vaginal challenge in 
macaques156. Both raltegravir and maraviroc protected humanized mice from vaginal 
challenge in an oral pre-exposure prophylaxis model157.
It is likely that clinical application of a microbicide will include inhibitors from at 
least two classes to increase effectiveness by targeting multiple stages in the viral 
lifecycle. However, resistance to microbicides is less likely than in systemic infection 
because the drug level at the site of application is very high (typically >1000-fold EC50) 
and the virus is not replicating under selective pressure (though individuals may be 
exposed to drug-resistant virus). However, combination microbicides would both reduce 
the likelihood of infection with resistant virus and increase efficacy. In the event that HIV 
infection has already occurred, the development of resistance would depend on systemic 
concentration, making identification of infections important prior to microbicide use.
Postexposure Prophylaxis
Administration of antiretroviral therapy after HIV exposure has shown to be 
effective in reducing the transmission rate to infants born to HIV infected mothers158-160, 
and can prevent infection in animal models if given within a limited time window161-163.
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PEP therapy has also been used to reduce the likelihood of infection in health care and 
clinical laboratory workers after accidental percutaneous exposure, with an 81% 
reduction in odds of infection 164 In the event that PEP therapy fails to prevent infection, 
initiation of therapy at the time of exposure may suppress the spread of the virus and 
reduce viral load, providing a means to limit the size of the latent reservoir. Indeed, the 
size of the latent reservoir, as measured by CD4+ T-cells harboring latent HIV-1 DNA, 
was found to be dramatically lower in patients who began ART therapy prior to 
seroconversion than those who initiated therapy in the chronic phase165. Additionally, the 
size of the reservoir appears to be correlated with the extent of CD4+ T-cell depletion 
prior to ART initiation166, which can be limited by early and aggressive ART therapy.
Conclusion
This thesis describes the development of D-peptide inhibitors of HIV-1, the 
generation of multimeric membrane-localized inhibitors to improve potency and reduce 
the kinetic limitation inherent to entry inhibitors, and strategies to improve the 
pharmacokinetic properties of these inhibitors. These inhibitors are very promising 
compounds for the prevention and treatment of HIV-1 with pM potency against 
pseudotyped HIV. Additionally, Chapter 5 includes a review of many non-natural 
peptide technologies and pharmacokinetic modifications to realize the significant benefits 
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The HIV gp41 N-trimer pocket region is an ideal viral target because it is extracellular, highly conserved, and 
essential for viral entry. Here, we report on the design of a pocket-specific D-peptide, PIE12-trimer, that is 
extraordinarily elusive to resistance and characterize its inhibitory and structural properties. D-Peptides 
(peptides composed of D-amino acids) are promising therapeutic agents due to their insensitivity to protease 
degradation. PIE12-trimer was designed using structure-guided mirror-image phage display and linker opti­
mization and is the first D-peptide HIV entry inhibitor with the breadth and potency required for clinical use. 
PIE12-trimer has an ultrahigh affinity for the gp41 pocket, providing it with a reserve of binding energy 
(resistance capacitor) that yields a dramatically improved resistance profile compared to those of other fusion 
inhibitors. These results demonstrate that the gp41 pocket is an ideal drug target and establish PIE12-trimer 
as a leading anti-HIV antiviral candidate.
The HIV envelope protein (Env) mediates viral entry into 
cells (11). Env is cleaved into surface (gpl20) and transmem­
brane (gp41) subunits that remain noncovalently associated to 
form trimeric spikes on the virion surface (16). gpl20 recog­
nizes target cells by interacting with cellular receptors, while 
gp41 mediates membrane fusion. Peptides derived from hep- 
tad repeats near the N and C termini of the gp41 ectodomain 
(N and C peptides) interact in solution to form a six-helix 
bundle, representing the postfusion structure (3, 55, 56). In this 
structure, N peptides form a central trimeric coiled coil (N 
trimer), creating grooves into which C peptides bind. This 
structure, in conjunction with the dominant-negative inhibitory 
properties of exogenous N and C peptides, suggests a mecha­
nism for Env-mediated entry (10, 22, 58-60).
During entry, gp41 forms an extended prehairpin interme­
diate that leaves the exposed N-trimer region vulnerable to 
inhibition for several minutes (18, 35). This intermediate ulti­
mately collapses as the C-peptide regions bind to the N-trimer 
grooves to form a trimer of hairpins (six-helix bundle), juxta­
posing viral and cellular membranes and inducing fusion. En- 
fuvirtide (Fuzeon), the only clinically approved HIV fusion 
inhibitor, is a C peptide that binds to part of the N-trimer 
groove and prevents six-helix bundle formation in a dominant- 
negative manner (61). Enfuvirtide is active in patients with 
multidrug resistance to other classes of inhibitors and is a 
life-prolonging option for these patients (30, 31). However,
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enfuvirtide use is restricted to salvage therapy due to several 
limitations, including (i) high dosing requirements (90 mg, 
twice-daily injections), (ii) high cost (~$30,000/year/patient in 
the United States), and (iii) the rapid emergence of resistant 
strains (21, 47).
A deep hydrophobic pocket at the base of the N-trimer 
groove is an especially attractive inhibitory target because of its 
high degree of conservation (3, 12, 48), poor tolerance to 
substitution (4, 34), and critical role in membrane fusion (2). 
Indeed, this region is conserved at both the amino acid level 
(for gp41 function in membrane fusion) and the nucleotide 
level (for the structured RNA region of the Rev-responsive 
element). Enfuvirtide binds to the N-trimer groove just N 
terminal to the pocket and is significantly more susceptible to 
resistance mutations than 2nd-generation C-peptide inhibitors, 
such as T-1249, that also bind to the pocket (8, 13, 29, 44, 46, 
47, 58).
Peptide design, molecular modeling, and small-molecule 
screening have produced a diverse set of com pounds that in­
teract with the gp41 pocket and inhibit HIV-1 entry with mod­
est potency, but often with significant cytotoxicity (7,14,15,17, 
23, 24, 26, 34, 51, 54). The first direct evidence that pocket- 
specific binders are sufficient to inhibit HIV entry came with 
the discovery of protease-resistant D-peptides identified using 
mirror-image phage display (12). In this technique, a phage 
library is screened against a mirror-image version of the target 
protein (synthesized using D-amino acids) (50). By symmetry, 
mirror images (D-peptides) of the discovered sequences will 
bind to the natural L-peptide target. As the mirror images of 
naturally occurring L-peptides, D-peptides cannot be digested 
by natural proteases. Protease resistance provides D-peptides 
theoretical treatment advantages of extended survival in the 
body and possible oral bioavailability (41, 42, 49).
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These lst-generation D-peptide entry inhibitors possess po­
tency against a laboratory-adapted isolate (HXB2) at low to 
mid-|xM concentrations (12). We previously reported an affin­
ity-matured 2nd-generation D-peptide called PIE7,pocket-spe- 
cific inhibitor of entry 7 (57). A  trimeric version of PIE7 is the 
first high-affinity pocket-specific HIV-1 inhibitor and has po­
tency against X4-tropic (HXB2) and R5-tropic (BaL) strains at 
sub-nM concentrations. However, significant further optimiza­
tion is required to create a robust clinical candidate for two 
reasons. First, this D-peptide is much less potent (requiring 
high nM concentrations) against JRFL, a primary R5-tropic 
strain. Therefore, improved PIE potency is necessary to com­
bat diverse primary strains. Second, by improving the affinity of 
our inhibitors for the pocket target, we hope to provide a 
reserve of binding energy that will delay the emergence of drug 
resistance, as described below.
We and others have reported a potency plateau for some 
gp41-based fusion inhibitors that is likely imposed by the tran­
sient exposure of the prehairpin intermediate (9, 27, 53, 57). 
For very high-affinity inhibitors, association kinetics (rather 
than affinity) limits potency so that two inhibitors with signif­
icantly different affinities for the prehairpin intermediate can 
have similar antiviral potencies. We proposed that overengi­
neering our D-peptides with substantial affinity beyond this 
potency plateau would provide a reserve of binding energy that 
would combat affinity-disrupting resistance mutations (57). 
Such a resistance capacitor should also prevent the stepwise 
accumulation of subtle resistance mutations in Env by elimi­
nating the selective advantage that such mutants would other­
wise confer.
Here, we report on the design and characterization of a 
3rd-generation pocket-specific D-peptide, PIE12-trimer, with 
~  100,000-fold improved target binding com pared to that of 
the best previous D-peptide, significantly broadened inhibitory 
potency, and an enhanced resistance capacitor that provides a 
strong barrier to viral resistance. We achieved this increased 
potency via structure-guided phage display and crosslinker op­
timization. PIE12-trimer has a dramatically improved resis­
tance profile compared to the profiles of earlier D-peptides, as 
well as those of enfuvirtide and T-1249. These results validate 
the resistance capacitor hypothesis and establish PIE12-trimer 
as a leading anti-HIV therapeutic candidate.
MATERIALS AND METHODS
Peptide synthesis. All peptides were synthesized as described previously (57). 
All dimers and trimers except PIE12-trimer were made essentially as described 
using bis-dPEG5 NHS ester (where PEG is polyethylene glycol and NHS is 
Af-hydroxysuccinimide; catalog no. 10224; Quanta BioDesign); PIE12-trimer was 
synthesized using the following higher-yield protocol. PIE12-GK (2 mM) was 
reacted with bis-dPEG5 NHS ester crosslinker (1 M stock in dimethylacetamide) 
at a 1:20 (peptide/PEG) molar ratio in 100 mM HEPES (pH 7.8 to 8) for 90 s at 
room temperature (RT). The reaction was stopped by addition of acetic acid to 
5% and 3 M guanidine HC1 (GuHCl) and purified by reverse-phase high-pres­
sure liquid chromatography (RP-HPLC; C18 column; Vydac). This product (~3 
to 5 mM) was reacted at a 2:1 molar excess with PIE12-GKK in dimethylacet­
amide buffered by triethylamine (pH 7.5) for 75 min and purified by RP-HPLC 
(C18 column; Vydac).
Phage display vector design. Use of a commercially available phage library 
cloning system (NEB) allowed us to relocate cloning sites away from the flanking 
regions (38). We redesigned the regions immediately outside the flanking resi­
dues in our cloning vector in order to structurally isolate them and minimize any 
bias caused by flanking sequence randomization. Our library peptides are dis­
played as fusions to the phage p3 protein, which contains an N-terminal leader
sequence that is cleaved by Escherichia coli secretion signal peptidases. In the 
original vector, the N-terminal flanking residues of the library peptides are 
immediately adjacent to the secretion signal. Due to proximity to the secretion 
signal cleavage site, it is likely that randomization of these residues would 
differentially affect library-p3 protein secretion and peptide presentation on the 
phage surface. This bias would confound the selection of N-terminal flanking 
sequences solely on the basis of their affinity for the N trimer. To avoid this bias, 
we introduced a five-amino-acid spacer to structurally isolate the cleavage site 
from the randomized N-terminal flanking residues. We choose the N-terminal 
residues (KIEEG) from maltose binding protein (MBP) as the spacer sequence, 
since MBP is very efficiently cleaved during secretion from E. coli.
We have observed that mutations in the C-terminal sequence that links the 
peptide to the phage p3 protein can also create undesirable selection bias (pre­
sumably by allowing the C terminus of the D-peptides to form a continuous helix 
with the N terminus of p3, thus enhancing peptide presentation to the target) 
(57). Therefore, a flexible GGGS spacer was inserted after the C-terminal flank­
ing residues to structurally isolate them from the N terminus of p3.
To validate this new phage display vector, we used it to clone an earlier PIE 
(PIE2) along with a mutant (PIE2-AAA) which had previously been observed to 
enhance phage affinity for the pocket target via mutation of the linker between 
the library peptide and p3, although this mutation did not enhance inhibitor 
potency when incorporated into a D-peptide (57). We assayed the target binding 
affinity of the resultant phage (O) and compared it to that of phage produced 
with the previous phage vector. In the previous phage vector, PIE2-AAA-0 
“cheated” in order to bind to the target with an ~70-fold more affinity than 
PIE2-0, but this difference was abolished in the modified vector (data not 
shown). Furthermore, sequencing revealed that N-terminal flanking residues 
from the amplified phage library prior to selection were random, indicating a lack 
of bias due to signal peptidase cleavage efficiency.
Phage display. An 8-mer flanking library phage display was performed essen­
tially as described previously (57). Four rounds of mirror-image solution-phase 
phage display were performed by incubating (for 2 h at RT) 1010 phage (ampli­
fied from the previous round) with 10 nM biotinylated D-IZN17 (a mimic of the 
D-peptide gp41 pocket target) in the presence of escalating soluble competitor 
(L-2K-PIE2) (10, 30, 90, and 360 |iM for rounds 1 to 4, respectively) (57). 
Phage-bound D-IZN17 was rapidly captured from solution using Dynal T1 
streptavidin-coated magnetic beads (Invitrogen) and briefly washed 3 times with 
500 |xl of 0.1% Tween 20 in Tris-buffered saline (wash buffer contained 100 fiM 
D-biotin for the 1st wash). Phage was eluted in 50 |xl of glycine (pH 2.2) elution 
buffer (10 min at RT) and neutralized with 7.5 |xl of 1 M Tris, pH 9.1. The 
amplified phage library was sequenced prior to the first round of selection to 
confirm randomization, and preamplified eluted phage was sequenced following 
each round. All phage binding experiments were performed using the same 
protocol described above using 270 |xM L-PIE2 soluble competitor. A  7-mer 
phage display was performed using a similar protocol.
Crystal growth and data collection. The original form of PIE12 (see Table 1) 
contains a C-terminal GK extension and did not yield highly diffracting crystals 
in complex with IQN17, a gp41 pocket mimic. Variants of PIE12 instead con­
taining an N-terminal K or KG extension (K-PIE12, KHPCDYPEWQWLCEL; 
KG-PIE12, KGHPCDYPEWQWLCEL) crystallized in complex with IQN17 
under a variety of conditions. In each case, the reservoir (850 |xl) comprised a 
solution from a commercially available crystallization screen, and the crystalli­
zation drop was prepared by mixing 0.3 or 0.5 |xl of the IQN17-PIE12 or 
IQN17-PIE71 protein solution (1:1.1 molar ratio, 10 mg/ml total in water) with
0.3 |xl of the reservoir solution. Crystals typically grew in 1 to 10 days. All crystals 
were grown by sitting-drop vapor diffusion. IQN17-PIE12 form I crystals (KG- 
PIE12) were grown at 21°C in Hampton Scientific condition Screen II 48 (10% 
PEG 20,000, 0.1 M bicine, pH 9.0, 2% dioxane). IQN17-PIE12 form II crystals 
(KG-PIE12) were grown at 21°C in Emerald Biosystems condition Cryo-II 37 
(50% ethylene glycol, 0.1 M imidazole, pH 8.0). IQN17-PIE12 form III crystals 
(K-PIE12) were grown at 4°C in Emerald Biosystems condition Cryo-II 25 (40% 
2-methyl-2,4-pentanediol (MPD), 0.1 M A^-cyclohexyl-3-aminopropanesulfonic 
acid (CAPS) [pH 10.5]). IQN17-PIE71 crystals were grown at 21°C in Qiagen 
PACT crystallization condition G4 (20% PEG 3350, 0.2 M potassium thiocya- 
nate, 0.1 M bis-Tris propane, pH 7.5).
Crystals were mounted in a nylon loop and either directly cryocooled by 
plunging them into liquid nitrogen or cryocooled following brief (20 s) immer­
sion in 20 fxl crystallization buffer with 30% (IQN17-PIE12) or 15% (IQN17- 
PIE71) added glycerol. Crystals were maintained at 100 K during data collection. 
Data were collected either in the laboratory using a rotating copper anode X-ray 
generator or at a synchrotron beam line. Data were processed using the DENZO 
and SCALEPACK programs (40). All structures were determined by molecular 
replacement using the PHASER program (33) with IQN17-PIE7 as the search
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model. The models were rebuilt using the O program (25) and refined against a 
maximum-likelihood target function using the REFMAC program (36). Struc­
tures were checked using the MolProbity program (6) (see Table 2 for data and 
refinement statistics).
Explanation of Lys placement. We were concerned that direct C-terminal 
addition of Lys would not be well tolerated because the D-peptide C-terminal 
region forms an a  helix critically involved in the pocket-binding interface, with 
the C terminus itself being amidated for helix stability. Therefore, we inserted a 
Gly between the original C terminus of PIE7 and the C-terminal Lys, both to cap 
the helix and to separate the Lys from the binding interface. Unexpectedly, 
PIE7-GK-monomer is slightly more potent than PIE7 (see Table 1). A version of 
PIE7 containing an N- and C-terminal Lys (K-PIE7-GK) has the same potency 
as PIE7-GK (data not shown), indicating a beneficial effect imposed by the 
C-terminal Gly-Lys, as opposed to a deleterious effect created by a single Lys at 
the N terminus. This benefit is likely the reason that the linkage consisting of an 
~22-A cross-linker at the C terminus whose spacer arm consists of 5 PEGs (C5C) 
results in a potency slightly superior to that of the N5C linkage (see Table 1).
Viral infectivity assays. Pseudovirion infectivity assays were performed as 
described previously (57). Purified lyophilized inhibitors were dissolved in water 
(monomers) or 50 mM HEPES, pH 7.5 (dimers and trimers), to make high- 
concentration stocks. For HEPES-containing samples, all media were adjusted 
so that the HEPES content matched that in the sample with the highest HEPES 
concentration (typically, ~1 mM). HEPES at higher concentrations (e.g., 3 mM) 
enhanced infectivity up to ~15% but had minimal effect at <0.5 mM. The 
Monogram Biosciences PhenoSense Entry and peripheral blood mononuclear 
cell (PBMC) assays were performed as described previously (43, 52).
CD studies. Samples were prepared with 2 |xM IZN17, a 1.1 X molar ratio of 
inhibitor to target binding sites, phosphate-buffered saline (PBS; 50 mM sodium 
phosphate, 150 mM NaCl, pH 7.4), and 2 M GuHCl in a total volume of 2.5 ml. 
Thermal melts were performed by melting the sample in a square 1-cm cuvette 
from 25°C to 90°C (or 93°C for PIE12-trimer) in 2°C increments with 2 min of 
equilibration. To show reversibility, reverse melts were performed on each sam­
ple from 90°C to 30°C in 10°C increments with 5 min of equilibration. Data were 
averaged from a 30-s collection on an Aviv model 410 circular dichroism (CD) 
spectrapolarimeter.
For each sample, the CD data followed a smooth sigmoid transition as the 
sample was heated or cooled. The data were smoothed in the Kaleidagraph 
program (Synergy Software) using 2 points from both sides. The derivative value 
of the smoothed data was used to determine the point with the steepest rate of 
change on the melt curve, which is the melting temperature (Tm).
Passaging studies. Laboratory-adapted HIV-1 strain NL4-3 was generated by 
transient transfection of proviral DNA (pNL4-3) into 293T cells using Lipo- 
fectamine (Invitrogen). Cell-free supernatants containing virus were collected 
48 h posttransfection and used to infect 5 X 105 CEM-1 cells in RPMI 1640 
medium (0.5 ml). Virus was serially propagated once a week by 1:5 dilution of 
cell-free viral supernatants into fresh CEM-1 cells (5 X 105 cells, 0.5 ml) in the 
absence or presence of inhibitor (PIE7-dimer, PIE12-dimer, or PIE12-trimer). 
Viral titers were monitored biweekly by p24 antigen enzyme-linked immunosor­
bent assay (PerkinElmer). The inhibitor concentration started at approximately 
the 50% inhibitory concentrations (IC50s; 20 nM for PIE7-dimer; 1 nM for 
PIE12-dimer, and PIE12-trimer) and was raised 1.5- to 2-fold when p24 antigen 
levels in inhibitor-containing cultures approached that in inhibitor-free cultures 
(usually 2 to 3 weeks for PIE7-dimer). PIE12-dimer and PIE12-trimer required 
a slower escalation strategy with prolonged incubation at a fixed inhibitor con­
centration for 5 to 15 weeks before escalation.
To identify PIE7-dimer escape mutations, viral RNA was isolated from cell- 
free supernatants of at least two cultures independently propagated in either the 
presence (resistant virus) or absence (control virus) of inhibitor (Qiagen RNA 
purification kit). Env cDNA was generated by reverse transcription (Eppendorf 
cMaster RTplus system and cMaster reverse transcription kit), amplified by 
PCR, and sequenced in five stretches (Thomas Jefferson University Nucleic Acid 
Facility). To confirm selected mutations in the gp41 N-peptide region, the cDNA 
segment encoding the gp41 ectodomain was reamplified by PCR and subcloned 
into the pAED4 vector, and the plasmid DNA from three or more individual 
clones was sequenced. The substitutions E560K and V570I were observed in all 
sequences from PIE7-dimer-resistant virus but were not observed in any se­
quence from control virus. An expression plasmid for HXB2 Env (pEBB_HXB2 
Env) incorporating these substitutions was generated using site-directed muta­
genesis (QuikChange; Stratagene) and was utilized in the pseudoviral infectivity 
assay described above.
Protein Data Bank accession numbers. The Protein Data Bank (PDB) acces­
sion numbers for the PIE12-IQN17 complex are 3L35, 3L36, and 3L37 for crystal 
forms I, II, and III, respectively, and 3MGN for the PIE71-IQN17 complex.




PIE7 KGA[PIE7]AA 620s 24,000*
PIE7-GK GA[PIE7]AAGK 390 16,000
PIE7-GKK GA[PIE7]AAGKK 380 19,000
PIE12 HP[PIE7]ELGK 37 580
PIE13C HP[PIE7]KL 41 1,500
PIE14 HP[PIE7]RLGK 33 1,100
PIE15 HA[PIE7]ELGK 67 1,400
N9N(PIE7)2 (KGA[PIE7]AA)2 1.9* 2,300s
N5C(PIE7)2 GA[PIE7]AAGKKGA[PIE7]AA 0.6 300
C5C(PIE7)2 (GA[PIE7]AAGK)2 0.5 200
C5C(PIE12)-, (HP[PIE7]ELGK)? 0.4 14
N9N(PIE7)3" (KGA[PIE7]AA)3 0.36 2206
C5C(PIE7)3 (GA [PIE7]A AG K )/ 0.1 6.7
C5C(PIE12)3 (H P[PIE7]ELG K )/ 0.5 2.8
C37 1.4s 13*
Enfuvirtide 3.76 5.06
a The IC50 standard error of the mean is <25% for duplicate assays for all 
values.
b Values are from reference 57.
c PIE13 does not include a C-terminal GK extension because its C-terminal 
flanking sequence contains a Lys residue. 
d The central peptide of each trimer has two tandem Lys residues (not shown). 
e PIE7, CDYPEWQWLC, or PIE7 core motif.
RESULTS
Structure-guided phage display to optimize flanking resi­
dues. PIE inhibitors consist of a short core sequence sur­
rounded by a disulfide bond that imparts structural rigidity 
required for binding (Table 1) (12). The large jump in affinity 
between our 1st-generation (12) and 2nd-generation (57) in­
hibitors was accomplished by optimizing this core sequence. 
There were also four fixed flanking residues outside the disul­
fide that arose from phage library cloning restrictions, Gly-Ala 
on the N terminus and Ala-Ala on the C terminus. Interest­
ingly, our cocrystal structures of D-peptides in complex with a 
mimic of its gp41 pocket target (IQN17) reveal significant 
contacts between these presumed inert flanking residues and 
the pocket (12, 57). Thus, we reasoned that their optimization 
would likely lead to improved D-peptide affinity for the pocket.
To optimize these flanking residues, we used a commercially 
available phage library cloning system (NEB) that allowed us 
to relocate cloning sites away from the flanking regions (38). 
We redesigned the regions immediately outside the flanking 
residues in our cloning vector in order to structurally isolate 
them and minimize any bias caused by flanking sequence ran­
domization. Using this vector, we constructed a phage library 
that varied only these four residues in the context of our 
previously optimized PIE7 core sequence (XXCDYPEWQW 
LCXX). After four rounds of panning, our phage library 
showed ~  100-fold improved binding to a gp41 pocket mimic 
(D-IZN17) compared to that of clonal PIE7 phage with the 
original GA/AA flanking sequence. We extensively sequenced 
this phage pool to identify a consensus sequence, H(A/P)- 
[PIE7 core]-(R/K/E)L, as well as five dominant individual se­
quences. Using a phage clone binding assay, we found that 
these sequences bound the gp41 pocket 70- to 900-fold more 
tightly than PIE7, with PIE12 (HP-[PIE7 core]-EL) having the 
highest affinity (data not shown).
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(Table 1 and Fig. 1). Pairwise comparisons of both phage 
binding and inhibitor potency indicate that Pro is preferred 
over Ala at position 2 and Glu is preferred over Arg or Lys at 
position 13. As predicted from the phage binding assay, PIE12 
has the best potency and is ~40-fold more potent than PIE7 
(our best previously reported monomer) against strain JRFL.
Crystal structure of PIE12. To better understand the 
sources of PIE12’s improved binding and potency, we crystal­
lized PIE12 in complex with the N-trimer pocket mimic 
1QN17. Data were collected from three crystal forms (Table 2) 
at between 1.45- and 1.55-A resolution. Each IQN17 trimer 
from the three crystal forms reported here and from the PIE7 
structure (PDB accession number 2R5D) agreed well with one 
another (root mean square deviation [RMSD], 0.6 to 1.2 A) on 
the basis of the least-squares overlap on all C„ atoms (residues 
1 to 45 of all three chains). The structures suggest two sources 
of the improved affinity of PIE12 for IQN17 compared to that 
of PIE7. First, the new N-terminal flank residues (Hisl and 
Pro2) form favorable ring stacking interactions with the pocket 
(IQN17-Trp571) (Fig. 2). Second, the substitution of Leu for 
Ala in the C-terminal flank sequence buries an additional 
-50-A 2 hydrophobic surface area in the pocket. Neither of 
these new interactions with the flanking sequence perturbs the 
original pocket-binding structure of the core PIE7 residues. 
Importantly, the structures reveal that PIE12’s improved affin­
ity does not result from new interactions with less conserved
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TABLE 2. PIE12 and PIE71 crystallographic data and refinement statistics
Data
Result for PIE12 crystal:
Result for PIE71 crystal
Form I Form 11 Form III
Space group P2i R3 P321 P2i
Resolution (A) 30.0-1.55 (1.61-1.55)“ 30.0-1.45 (1.50-1.45) 30.0-1.45 (1.50-1.45) 30.0-1.40 (1.45-1.40)
No. of reflections measured 113,335 98,687 186,351 468,599
No. of unique reflections 25,088 10,475 14,802 82,774
Redundancy 4.5 9.4 12.6 5.7
Completeness (%) 86.5 (66.8) 97.1 (80.1) 99.7 (96.6) 98.2 (97.6)
< I/a I> b 18 (2.4) 19 (3.1) 17 (2.7) 15 (2.0)
Mosaicity (degree) 0.44 0.37 0.45 0.29
R csym
Refinement
0.051 (0.250) 0.058 (0.102) 0.107 (0.235) 0.052 (0.316)
Resolution (A) 30.0-1.55 (1.59-1.55) 30.0-1.45 (1.49-1.45) 30.0-1.45 (1.49-1.45) 30.0-1.40 (1.44-1.40)
No. of reflections used for refinement 23,765 9,448 13,629 80,532
No. of reflections in R be/  set 1,273 1,026 1,136 1,654
R e■^cryst 0.232 (0.465) 0.234 (0.301) 0.243 (0.299) 0.261 (0.306)
■ftfree 0.288 (0.624) 0.264 (0.392) 0.278 (0.350) 0.288 (0.335)
RMSD bonds (A)/angles (degrees) 0.012/1.440 0.013/1.693 0.010/1.530 0.009/1.094
All atoms (A2)/no. of atoms 23.7/1,172 31.9/384 29.2/384 Mol^ 1, 24.3/1,555; mol 2, 
36.0/1,491
PIE12 molecules only (A2)/no. of atoms 21.3/420 30.8/144 25.9/144 Mol 1, 18.3/368; mol 2, 
39.9/322
Water molecules (A2)/no. of water atoms 32.0/197 38.0/36 40.6/49 39.9/389
<J)/Mr/i most favored (%) 100 98.1 100 99.0
“ Values in parentheses refer to data in the high-resolution shell.
b <I/aI>, average intensity of a group of reflections divided by the average standard deviation (sigma) of the same group of reflections. 
cR sym = 2 |/ — < /> |/2 /, where I  is the intensity of an individual measurement and < />  is the corresponding mean value. 
d ^ free is the same as Rctyst calculated with a randomly selected test set of reflections that were never used in refinement calculations, 
'^cryst = S||Fo| — |Fc||/2|-Fo|, where |Fo| is the observed and Fc\ is the calculated structure factor amplitude.
 ^Mol, molecule.
* < B >, temperature factor. 
h dihedral angles.
Cone (uM)
FIG. 1. Optimization of flanking residues enhances PIE potency. 
Each point represents the average of quadruplicate measurements from a 
representative pseudovirion entry inhibition assay (JRFL strain) normal­
ized to the measurement for an uninhibited control. Error bars represent 
the standard errors of the means. PIE12 is ~2-fold more potent than 
PIE13 or PIE14 and is ~25-fold more potent than PIE7-GK.
Enhanced potency of 3rd-generation D-peptides. We synthe­
sized D-peptides corresponding to the top three phage se­
quences in the binding assay (PIE12, PIE13, and PIE14) and 
tested their antiviral potencies in a pseudovirion entry assay
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FIG. 2. Crystal structure of PIE12 binding to IQN17. Trp571 of the 
gp41 pocket (gray) and the N-terminal flank residues (dH l and dP2) of 
PIE12 (green) appear to stabilize binding via ring-stacking interac­
tions. The disulfide bond (yellow) is shown in the background.
regions outside the pocket that might render PIE12 more vul­
nerable to resistance mutations.
Discovery and structure of a 7-mer D-peptide. The core 
sequence of PIE7 and PIE12 comprises 8 residues flanked by 
cysteines (8-mer). Modeling based on our 8-mer D-peptide/ 
IQN17 crystal structures suggests that a 7-mer core is compat­
ible with pocket binding of the WXWL consensus and forma­
tion of a disulfide bond (57). Previously, we saw that decreasing 
the size of the PIE core (from 10 to 8 residues) led to dramat­
ically increased pocket binding (57), so we reasoned that fur­
ther decreasing the size of the core might lead to additional 
potency gains. To explore this alternative geometry, we used a 
mirror-image discovery process similar to that employed with 
8-mers to identify a 7-mer, PIE71 (FVCPPEWRWLCDL). 
PIE71 contains the same WXWL motif found in 8-mer and 
10-mer pocket binders and inhibits strain HXB2 entry with an 
IC50 of 410 nM (data not shown), which is —1.5 fold better 
than that of PIE7 but an order of magnitude worse than that of 
PIE12.
To gain a better understanding of the 7-mer binding solu­
tion, we determined a cocrystal structure of PIE71 in complex 
with IQN17 (Table 2). The key residues involved in the binding 
interface (WXWL) adopt nearly superposable conformations 
to those observed in PIE7 and PIE12, as do the C-terminal 
flank residues. However, the two structures deviate signifi­
cantly at the N terminus (Fig. 2 and 3). Specifically, the 7-mer’s 
disulfide bond is shifted much closer to the pocket, which 
directs the N-terminal flank residues away from the pocket 
region. As a result, the N-terminal flanking residues (Phe-Val) 
only graze the pocket, whereas PIE12’s N-terminal flanking 
residues have an intimate interaction. So although the 7-mer is 
compatible with pocket binding, the smaller core is too con­
strained to allow optimal binding of the flank residues to the 
pocket. Due to this decreased binding interface and therefore 
decreased potency, we decided not to pursue the 7-mer geom­
etry further.
Optimization of crosslinker length and geometry. We pre­
viously took advantage of the trimeric nature of the gp41
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FIG. 3. Crystal structure of PIE71 binding to IQN17. The N-ter- 
minal flank residues (dF l and dV2) of PIE71 (orange) are directed 
away from the pocket compared to the structure in PIE12 (Fig. 2). The 
disulfide bond (yellow) is shown in the background.
pocket target to geometrically increase the PIE7 binding affin­
ity by cross-linking it into dimers and trimers (57). PIE7 has an 
N-terminal lysine, which furnishes a unique primary amino 
group (the N terminus is acetylated) and which was added for 
solubility. This lysine was used to produce dimers via reaction 
with a bis-PEG NHS ester crosslinker (NHS esters selectively 
react with primary amino groups). Trimers were produced by 
cross-linking two PIE7s to a central peptide with two lysines at 
the N terminus (2K-PIE7).
We hypothesized that the strength of the avidity effect is 
related to the length of the crosslinker and that shorter 
crosslinkers that still allow simultaneous binding to multiple 
pockets could strengthen potency. For the original N- to N- 
terminal linkage, we used a crosslinker with an —35-A spacer 
arm consisting of 9 PEG units (N9N linkage). However, our 
crystal structures of D-peptides in complex with IQN17 reveal 
that C- to C-terminal or N- to C-terminal linkages could be 
significantly shorter and could be spanned by an —22-A 
crosslinker whose spacer arm consists of 5 PEGs (C5C and 
N5C linkages). Therefore, we relocated Lys to the C terminus 
of PIE7 (PIE7-GK) in order to make the NSC heterodimers 
and C5C homodimers (see Materials and Methods for addi­
tional details).
The resulting N5C- and CsC-PIE7-dimers have similar po­
tencies that are significantly enhanced compared to the po­
tency of our previous N9N-PIE7-dimer (Table 1 and Fig. 4A). 
On the basis of these data, we chose C5C connections as our 
standard linker, since they are simpler to produce than the 
hetero-N5C linkage. Here, all dimers and trimers use the C5C 
linkage unless otherwise specified. Combining our new opti­
mized flanking residues and linkages, we produced PIE12- 
dimer and PIE12-trimer. Both are extremely potent against the 
difficult-to-inhibit primary strain JRFL (low-nanomolar IC50s; 
Fig. 4B; Table 1), being up to 2 orders of magnitude more 
potent than our best previously described D-peptide (N9N 
PIE7-trimer) (57).
Breadth against a diverse multiclade panel. HIV-1 has 
jumped from chimpanzees to humans at least three separate 
times, giving rise to groups M, N, and O (19). The main group 
(group M) accounts for >99% of all HIV-1 infections world-
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PIE7-trimer PIE12-trimer PIE 12- monomer Enfuvirtide
92UG029 A 1.6 0.7 290 190
92UG037 A 0.1 0.2 36 41
93TH073 AE 0.6 0.8 270 200
CMU02 AE 0.2 0.4 300 44
CMU06 AE 0.3 0.4 210 5.7
IIIB B 0.3 0.8 140 28
BaL B 0.2 0.3 72 20
JRCSF B 0.1 0.1 120 7.0
JRFL B 0.5 0.3 110 1.7
93BR019 BF 1.7 4.7 170 >1,000
92BR025 C 15 5.2 >1,000 310
93IN101 C 0.4 0.4 160 22
92UG001 D 0.8 4.5 230 180
92UG046 D 0.1 1.2 170 130
93BR020 F 0.2 0.4 190 59
93BR029 F 0.2 0.8 86 19
G3 G 0.3 1.2 310 23
RU570 G 0.3 0.4 480 37
BCF01 Group O >1,000 >1,000 >1,000 330
BCF02 Group O >1,000 440 >1,000 0.4
PIE12 in complex with IQN17 reveal that, of these residues, 
the D-peptide directly interacts only with K574 (via a hydro­
phobic interaction) and Q577 (via hydrogen bonds). Group O 
gp41 has several other mutations in the groove just outside the 
pocket (i.e., H564E) that could also affect PIE potency (e.g., by 
slowing the association rate). It will be interesting to analyze 
the effects of these mutations in a group M (e.g., strain HXB2 
or JRFL) background to see if they are responsible for the loss 
of potency.
Evidence for a charged resistance capacitor. With the design 
of PIE12-trimer, we now observe strong evidence for a highly 
charged resistance capacitor in which the PIE12-trimer pocket- 
binding affinity vastly exceeds the inhibitory potency. Compar­
ing PIE7 and PIE12-trimers, we observe similar potencies 
against pseudovirion entry (Fig. 4B; Table 1), although we 
expect their target affinities to be extremely different.
Due to extraordinarily slow off rates, direct measurements of 
the pocket affinities for PIE7 and PIE12-trimers via surface 
plasmon resonance, used for earlier D-peptides (57), were not 
possible. Since the binding affinity of inhibitors correlates with 
the stability of inhibitor-target complexes, we used thermal 
denaturation monitored by CD to measure the relative stabil­
ities of each IZN17-inhibitor complex and infer the relative 
affinities of our ultra-high-affinity binders. The melts were per­
formed in 2 M GuHCl to destabilize the complexes and shift 
their melting points into an observable range (below 100°C).
The normalized thermal melts for each IZN17-inhibitor 
complex are plotted in Fig. 5, with Tm values being shown in 
the key. As expected, PIE12-trimer forms the most stable com­
plex and has a Tm 8°C higher than that of the next most stable 
inhibitor complex (PIE7-trimer). PIE12 also forms a more 
stable complex than PIE7, as expected. Our previous experi­
ence showed that improvements in monomer affinity translated 
to approximately squared and cubed improvements in the cor­
responding dimers and trimers (57). On the basis of PIE12- 
trimer’s optimized CSC linkage (35-fold improved antiviral po­
tency over that of the trimer with an N9N linkage; strain JRFL 
data) and the ~25-fold difference in monomer potency be­
tween PIE7 and PIE12 (JRFL data), we estimate that PIE12- 
trimer binds to gp41 >105-fold (35 X  253) more tightly than 
N9N PIE7-trimer. This predicted binding at subfemtomolar 
concentrations translates to a resistance capacitor charged to 
~ 6  kcal/mol against strain JRFL. Interestingly, the potency 
plateau lies at a slightly better potency for trimers than for 
dimers, likely due to their faster association rates (i.e., three 
versus two opportunities for initial collision with the target).
Selection of resistant strains. To measure the resistance 
profile of our D-peptide inhibitors and test our resistance 
capacitor hypothesis, we conducted viral passaging studies 
with escalating inhibitor concentrations to select for resis­
tant strains. These studies initially used PIE7-dimer, which 
was available from our previous study (57) and inhibits the 
parental strain, NL4-3, with an ICS0 of —20 nM. By doubling 
the PIE7-dimer concentration every 2 to 3 weeks, we ob­
tained stable viral cultures in 2,000 nM inhibitor within 20 
weeks of propagation. In comparison, we were able to ob­
tain high-level enfuvirtide resistance (>1,000-fold) in only 
~ 3  weeks using a similar protocol (H. K. Steger et al., 
submitted for publication).
Sequencing the N-peptide region of PIE7-dimer-resistant 
viruses revealed two selected mutations: E560K and V570I. 
These substitutions in the context of HXB2 pseudovirions con­
ferred ~400-fold resistance to PIE7-dimer. These mutations 
also dramatically weaken the binding of D-peptides to the gp41 
pocket but not the C-peptide inhibitor C37 (M. J. Root et al., 
unpublished data). It is not obvious from the PIE7 structure 
how these mutations weaken PIE7 binding. Despite this loss of 
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FIG. 5. Stability of D-peptide complexes. Normalized melting 
curves of IZN17 alone and with D-peptide inhibitors were monitored 
by CD in PBS-2 M GuHCl. Tm values are indicated in the key.
51






PIE7-dim er PIE12-dim er PIE12-trim er C37
FIG. 6. Effect of PIE7-dimer resistance mutations on PIE7-dimer, 
PIE12-dimer, and PIE12-trimer potency. IC50s against wild-type (wt) 
and PIE7-dimer-resistant (E560K/V570I) strain HXB2 pseudovirion 
entry are shown. The C-peptide inhibitor C37 is included as a control. 
D ata represent the means from at least two independent experiments. 
Error bars represent the standard errors of the means.
potencies of PIE12-dimer and PIE12-trimer, as well as the C37 
control inhibitor (Fig. 6). This result is predicted by the resis­
tance capacitor hypothesis: affinity-disrupting escape muta­
tions selected in the presence of weaker-binding inhibitors 
should be less disruptive to the potencies of tighter-binding 
inhibitors.
The rapid inhibitor escalation strategy utilized to generate 
PIE7-dimer resistance was not effective in generating HIV-1 
resistant to PIE12-dimer or PIE12-trimer. Rather, the HIV-1 
titer fell precipitously when inhibitor concentrations exceeded 
20 nM (5 to 20 times the ICS0). Instead, we switched to a much 
slower escalation strategy with prolonged periods at stable 
inhibitor concentrations (5 to 15 weeks). Resistant virus 
emerged after 40 weeks of propagation in PIE12-dimer and 
after 65 weeks of propagation in PIE12-trimer. These obser­
vations suggest that a strong resistance capacitor profoundly 
delays selection of resistance mutations for these optimized 
fusion inhibitors.
Sequencing of the pocket region of PIE12-trimer-resistant 
viruses reveals only one mutation, Q577R. Interestingly, this 
substitution is present in nearly all group O isolates (including 
BCF01 and BCF02; Table 4) but is rare among group M 
isolates. Pseudovirions bearing Q577R confirm that this muta­
tion confers substantial resistance to PIE12-trimer (data not 
shown). Examination of the PIE12 crystal structure shows that 
Q577 makes hydrogen bonds with Glu7 and TrplO in PIE12, 
which may explain the disruptive effects of this mutation. 
Q577R’s codon is predicted to disrupt the RRE stem-loop V 
structure, since it base pairs with the invariant W571 codon 
(Trp is encoded by only one codon).
DISCUSSION
PIE12-trimer is a D-peptide entry inhibitor with ~80-fold 
enhanced potency and an estimated >  100,000-fold improved 
binding affinity compared to those of the best previously re­
ported D-peptide. This dramatic improvement in affinity pro­
duces excellent breadth and a charged resistance capacitor to 
combat the emergence of resistance mutations. Indeed, PIE12- 
trimer was able to withstand the impact of resistance mutations 
to earlier D-peptides and required a much longer selection (65 
weeks) to generate resistant strains. Ongoing work is exploring 
the mechanism of PIE7-dimer, PIE12-dimer, and PIE12-tri- 
mer resistance and its relationship to group O’s insensitivity. A 
key question is whether HIV can develop resistance to these 
inhibitors independent of changes in affinity (e.g., kinetics) that 
are capable of maintaining viral fitness.
Viral escape affects even the newest class of FDA-approved 
HIV-1 drugs, integrase inhibitors. Resistance to raltegravir and 
corresponding treatment failure were observed in a significant 
subset of patients in both the phase II and III clinical studies 
(5), and corresponding resistance mutations can be seen within 
4 weeks when resistant virus is selected in viral passaging stud­
ies (28). Our studies indicate that PIE12-trimer is a promising 
entry inhibitor that could overcome the limitations associated 
with the two currently approved entry inhibitors, enfuvirtide 
(high dosing, susceptibility to resistance) and maraviroc (Sel- 
zentry; effective only against R5 viruses) and may also prove to 
have a better resistance profile than even the newest class of 
HIV-1 inhibitors.
In addition to being a possible therapeutic agent, PIE12- 
trimer is an ideal candidate for a topical microbicide, as its 
protease resistance would allow it to withstand the protease- 
rich environment of the vaginal mucosa. In the absence of a 
safe and effective HIV vaccine, a topical microbicide to pre­
vent the sexual transmission of HIV is an urgent unmet global 
health need. The ultimate utility of PIE12-trimer as a micro­
bicide or therapeutic agent will be determined by advanced 
preclinical and clinical studies, including characterization of 
pharmacokinetics, in vivo toxicity, effectiveness in animal mod­
els of HIV infection (alone or in combination with other HIV 
inhibitors), and optimization of formulations for microbicide 
gels or vaginal rings.
More generally, the present work unequivocally shows that 
D-peptide inhibitors can be designed with high potency and 
specificity against natural L-protein targets. The D-peptide de­
sign methodology described here can be applied to diverse 
biomedical applications, particularly for the many viruses that 
share HIV’s hairpin-closing entry mechanism (e.g., influenza 
virus, Ebola virus, respiratory syncytial virus, severe acute re­
spiratory syndrome coronavirus, Dengue virus, and West Nile 
virus). Our resistance capacitor design strategy may also be 
generally applicable for treating other rapidly evolving dis­
eases, especially when combined with recent advances in an­
ticipating likely structural sources of drug resistance (37). Fi­
nally, the development of PIE12-trimer as a strong clinical 
candidate will allow D-peptide therapeutics to be evaluated in 
vivo to determine if their theoretical advantages warrant a 
prominent role as a new class of therapeutic agents.
J. V i r o l .
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A BSTRA CT: T he  highly conserved HIV-1 gp41 "pocket” region is a prom ising target for 
inhibiting viral entry. PIE12-trim er is a p ro  tease-resistant trim eric D-peptide inhibitor tha t binds to 
this pocket and po ten tly  blocks H IV  entry. PIE12-trim er also possesses a reserve o f binding 
energy tha t provides it w ith a s trong genetic barrier to  resistance ("resistance capacitor”). H ere, we 
repo rt the  design o f a m odular scaffold em ploying PEGs o f discrete lengths for the efficient 
optim ization and synthesis o f PIE12-trim er. This scaffold also allows us to  conjugate PIE12-trim er 
to  several m em brane-localizing cargoes, resulting in dramatically im proved potency  and re ten tion  
o f PIE12-trim er’s ability to  absorb the  im pact o f resistance m utations. This scaffold design strategy 
should be o f b road utility for the  rapid p ro to typing o f m ultim eric peptide inhibitors attached to 
potency- or pharm acokinetics-enhancing groups.
A
■  INTRODUCTION
H IV  en try  is m ed ia ted  by  th e  trim eric  viral envelope 
glycoprotein (Env), w hich is cleaved into surface (g p l2 0 ) 
and transm em brane (g p 4 l)  subunits.1,2 Viral en try  is triggered 
by  binding o f g p l2 0  to  a prim ary receptor (C D 4) and 
subsequently  a coreceptor (typically CXCR4 o r C C R 5), which 
induces large conform ation changes in g p l2 0  tha t activate gp41 
for fusion.3 gp41 th en  adop ts  an ex tended  p re-ha irp in  
conform ation, em bedding its N -term inal hydrophobic fusion 
peptide in to  the  host cell m em brane, bridging the  virus and the 
host cell (Figure l ) .  In  this state, the  gp41 N -peptide region 
forms a trim eric coiled-coil (N -trim er), while the  C -peptide 
region is in a structurally undefined state. This pre-hairpin 
interm ediate then  slowly collapses in to  a hairpin structure, with 
the  C -peptide folding back upo n  the N -trim er to  pack in an 
antiparallel orientation in to  the  grooves o f the N -trim er. T he 
form ation o f this trim er-of-hairpins structure brings the viral 
and host m em branes into close proxim ity and drives m em brane 
fusion.4,5
In  the  pre-hairp in  interm ediate, gp41 is vulnerable to 
inhibitors tha t b ind  to  either the  N -trim er or C -peptide2,6 
and prevent hairpin form ation.7-9 This vulnerability has been  
exp lo ited  by  th e  C -p ep tid e -d e riv ed  th e rap eu tic  F uzeon  
(enfuvirtide). Fuzeon binds to  a po rtion  o f the  N -trim er 
groove, preventing fusion w ith nanom olar potency. T hough 
effective, Fuzeon is currently utilized only as "salvage therapy” 
for patients w ith m ultidrug resistance because o f its high cost 
(~ $ 3 0  0 0 0 /y ea r/p a tien t), dosing requirem ents (90 m g twice 
daily), injection site reactions, and the  rapid em ergence o f 
resistant strains.10,11
T he gp41 N -trim er contains a functionally critical and highly 
conserved deep hydrophobic pocket at its C -term inus.4,12,13 
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Figure 1. HIV entry pathway. Upon engagement with cellular receptor 
and coreceptor, gpl20 and gp41 undergo a conformational change 
resulting in extension of gp41 into the pre-hairpin intermediate, 
exposing the hydrophobic pocket region of the N-trimer. gp41 
collapses into the trimer-of-hairpins structure, juxtaposing the viral and 
host membranes and causing membrane fusion. The hydrophobic 
pocket targeted by PIE12 is an estimated 60 A from the cell 
membrane, which can be bridged by a relaxed PEG24 linker. In 
contrast, the C-peptide C-terminus is directly adjacent to the 
membrane. Cholesterol (red) conjugated with PEG spacers (black 
lines) are shown.
structured  R N A  region o f the Rev-responsive elem ent (RRE), 
w hich is critical for the  export o f viral m R N A  to  the  
cytoplasm ,14 further constraining evolution o f this region on
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the nucleotide level. Fuzeon binds to the N-trimer groove 
region just outside the pocket, an area that is more tolerant of 
resistance mutations. Second/third-generation C-peptide in­
hibitors (e.g, T 1249, T2635) bind the groove and pocket and 
are much less susceptible to resistance.10’15 20
We have utilized structure-guided mirror-image phage 
display to generate D-peptide inhibitors that bind with high 
affinity to the pocket. ’ ’ D-Peptides are protease resistant 
(as proteases have stereochemical specificity and generally only 
cleave L-substrates), giving them the potential for a much 
longer lifetime in the body. PIE 12, our most potent monomeric 
D-peptide, is a pocket-specific inhibitor of HIV-1 with high-nM 
potency against the difficult-to-inhibit primary HIV isolate 
JRFL. Since the N-trimer contains three symmetric pockets, we 
designed a trimeric version of PIE 12 that uses PEG to link 
three monomers and greatly improves affinity and potency via 
avidity. PIE 12-trimer inhibits all major HIV clades with high- 
pM to low-nM potency and is a promising preclinical 
candidate for the treatment and prevention of HIV-1. Here, we 
describe a novel modular PEG scaffold used to optimize the 
production and the potency of PIE12-trimer.
While designing D-peptide inhibitors with progressively 
greater potency, we encountered a potency limit that could 
not be overcome by affinity optimization because the target is 
only available in the short-lived pre-hairpin intermediate. Due 
to the finite target exposure and the limits of diffusion, the 
potency of inhibitors with very high affinities (and on-rates) is 
limited by the diffusion-limited on-rate rather than binding 
affinity. For such diffusion-limited inhibitors, a potency plateau 
is reached beyond which further improvements in affinity do 
not improve potency. Similar potency plateaus have been 
observed for several inhibitors that target the transient pre­
hairpin intermediate.21,22’24-2 “Over-engineering” our inhib­
itors with improved affinity, but no corresponding improve­
ment in potency, provides a reserve of binding energy and 
slows the evolution of resistance mutations. This “resistance 
capacitor” eliminates the selective advantage conferred by 
affinity-disrupting resistance mutations, since viruses bearing 
mutations that reduce affinity are still inhibited with equal 
potency, depriving HIV of an efficient evolutionary pathway to 
resistance. A profoundly disruptive mutation could escape the 
resistance capacitor, but such severe pocket mutations are 
discouraged due to the high cost to viral fitness. With high pM 
to low nM potency but sub-fM binding affinity, PIE 12-trimer 
has a very strong resistance capacitor.
We hypothesize that potency could be improved beyond the 
plateau by pre-positioning inhibitor on the cell surface, the site 
of viral entry, thus increasing the association rate beyond the 
diffusion limit. Using our novel modular PEG scaffold, we 
conjugate PIE12-trimer to membrane-localizing groups (cho­
lesterol and alkyl chains) that improve potency up to ~160- 
fold. This approach greatly simplifies trimer synthesis and 
improves yield. Importantly, our data show that this gain in 
potency does not disrupt the resistance capacitor, leaving intact 
PIE12-trimer’s strong barrier to resistance mutations. Using a 
discrete PEG scaffold with orthogonal reactive groups and 
defined geometry allows for rapid optimization of multimeric 
inhibitors and scouting of various potency-enhancing cargoes 
and should be of broad utility for the design of other 
multimeric peptide inhibitors.
■  EXPERIMENTAL PROCEDURES
Peptide Synthesis. Peptides were synthesized using a PTI 
PS3 peptide synthesizer or by RS Synthesis as previously 
described21'22 to generate either PIE12-GK or AHP-PIE12-GK 
(lacks two N-terminal residues, D-His and D-Pro). PIE12- 
dPEG4/s-NH2 (the precursor to PIE12-trimer synthesis) was 
synthesized as follows: PIE12-GK (10 mM in dimethylaceta- 
mide, DMAC) was reacted with 250 mM stock solution of 
Fmoc-N-amido-dPEG4/s-NHS ester (Quanta BioDesign 10994 
and 10053) in dry DMAC (Acros Organics, septa sealed with 
molecular sieves) at a 1:1 molar ratio buffered by triethylamine 
(200 mM, pH 7.5) for 60 min at RT. This reaction was 
quenched by addition of acetic acid to 5% and purified by 
reverse-phase HPLC (water/acetonitrile gradient in 0.1% TFA) 
on a Waters BEH X-Bridge 10 fim, 300 A C18 column (RP- 
HPLC). Purified product was lyophilized, then resuspended in 
20% piperidine in DMAC for 20 min to remove Fmoc and 
produce PIE12-PEG4/s-NH2, which was then purified by RP- 
HPLC.
Trimer Synthesis. PIE12-PEG4/S-NH2 (10 mM) was 
reacted with 250 mM stock solution trimethylolethane-triNHS 
ester (Figure 2A, Quanta BioDesign 10674) in DMAC at a
h
0 Jt
Figure 2. Trimeric and heterotetrameric PEG scaffolds and cargoes. A. 
Trimethoylethane-triNHS ester. B. Heterotetrameric PEG scaffold. 
The fourth maleimide arm is available for reaction with thiol- 
containing cargoes, such as 1-octadecanethiol (C18-SH) and 
thiocholesterol.
3.3:1 (peptide/scaffold) ratio in DMAC buffered by triethyl­
amine (200 mM, pH 7.5) for 60 min at RT. Product was 
purified by RP-HPLC. All masses were confirmed by ESI-MS 
(AB Sciex API-3000).
Cholesterol-PIE12-trimer and alkyl-PIE12-trimer were syn­
thesized as follows: PIE12-PEG4-NH2 (10 mM) was reacted 
with Maleimide-PEG12-triNHS ester (Quanta BioDesign 
10676, 250 mM in DMAC) or Maleimide-PEG24-triNHS 
ester (Figure 2B, Quanta BioDesign 10680, 250 mM in 
DMAC) at a 3.3:1 (peptide/scaffold) ratio in DMAC buffered 
by triethylamine (200 mM, pH 7.5) for 45 min at RT. 
Thiocholesterol (Sigma Aldrich, 136115, 250 mM in chloro­
form), 1-octanethiol (Sigma-Aldrich 471836), 1-hexadecane- 
thiol (Sigma-Aldrich 52270), or 1-octadecanethiol (Sigma 
Aldrich 01858) were then added to a final concentration of 
4.5 mM and reacted for an additional 60 min. For PEG16, 
PIE12-PEG4-NH2 was first reacted with Mal-PEG12-triNHS 
ester, followed by reaction with D-Cysteine (5 mM) to yield 
(PIE12-PEG4)3-PEG12-Cys. This product was then purified by 
RP-HPLC before sequential reaction with Maleimide-PEG4- 
NHS and thiocholesterol under conditions identical to those 
used to generate chol-PEG^-PIE 12-trimer. PEG36, PEGS7, and 
PEG132-trimer were produced through conjugation of PIE12-
1253 dx.do i.org/10 .1021/bc300076flB /oconyugate Chem. 2012, 23, 1252 -1258
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PEG4-NH2 to Maleimide-PEG24-triNHS ester, followed by 
addition of D-cysteine. T his intermediate was th en  conjugated 
to Mal-PEG12-NHS ester (Quanta Biodesign, 10284), Mal- 
PEG2K-NHS ester (Creative PEGWorks, PHB-950, ~45 PEG 
units), or Mal-PEG5K-NHS ester (Creative PEGWorks, PHB- 
952, ~120 PEG units) to yield Chol-PEG36-PIE12-Trimer, 
Chol-PEGS7-PIE 12-trimer, and Chol-PEG132-PIE12-trimer, re­
spectively. The reaction was quenched by addition of acetic acid 
to 5% before purification by RP-HPLC.
Viral Infectivity Assays. Pseudovirion infectivity assays 
were carried out as previously described21,22 using HXB2 and 
JRFL luciferase reporter pseudovirions (NL4—3 strain) and 
HOS-CD4-CXCR4 (for HXB2) or HOS-CD4-CCR5 (for 
JRFL) target cells. Inhibitor curves were generated using six 
concentration points measured in quadruplicate, and luciferase 
counts were normalized to an uninhibited control. Inhibition 
curves were fit using a standard ICS0 eq [1 — c/(lC S0 + c)] 
weighting each concentration point by its standard error in 
KaleidaGraph (Synergy software). Reported ICS0 values are the 
average of at least 2 independent assays.
■  RESULTS
Our first goal was to simplify the synthesis of PIE12-trimer 
while also optimizing the linkages between PIE12 monomers. 
In our previous work, we synthesized PIE12-trimer by attaching 
bis-NHS ester PEGS spacers to PIE12-GK. After purification, 
two of these PEGylated monomers were reacted with a central 
PIE12-GKK monomer (two primary amines) to produce 
PIE12-trimer.21 This method is cumbersome for large-scale 
production, because it requires the synthesis of two distinct d- 
peptides and a series of HPLC purifications to assemble the 
trimer, resulting in low yields. In addition, our PIE 12 crystal 
structure suggested that shorter PEG linkers might adequately 
bridge the neighboring pockets and improve avidity. To address 
these goals, we redesigned the PIE12-trimer using a scaffold 
strategy. We designed a homotrimeric scaffold containing three 
NHS ester arms for conjugation to PIE12-GK (Figure 2a) in a 
single-pot reaction. PEG linkers of various lengths can be 
appended to the PIE12-GK peptide, allowing for the simple 
production of PIE12-trimers with varying PEG lengths.
PIE12-trimer’s estimated sub-fM affinity for the N-trimer 
makes direct comparative KD measurements (e.g., by surface 
plasmon resonance) very challenging. Although antiviral 
potency can be used as a surrogate for affinity, PIE12-trimer’s 
potency plateau can mask even large changes in affinity. To 
overcome this problem, we designed a PIE 12 variant with 
weakened affinity to allow comparative evaluation of different 
trimer geometries by measuring inhibitor potency. We 
previously observed that PIE12’s two N-terminal residues 
make important contacts with the N-trimer and reasoned that 
deletion of these residues (D-His and D-Pro) would significantly 
reduce binding affinity without disrupting the overall 
orientation of PIE12 binding to the gp41 pocket or the local 
structure at the C-terminal PEG linkage site. AHP-PIE12 is 84­
fold less potent than PIE12 (Table l). In the context of the 
homotrimeric scaffold, AHP-PIE12 connected via our standard 
PEGS linkers has an ICS0 of 380 nM against HXB2 (a standard 
lab-adapted strain) and is therefore well outside of the potency 
plateau (~500 pM for HXB2). Using AHP-PIE12-trimer, we 
can now detect changes in potency due to linker changes that 
subtly alter affinity.
Our initial exploration of PEG linker lengths in PIE 12-trimer 
showed that PEG2 and PEG3 were slightly less potent than the
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Table 1. D-Peptide Inhibition Data“
ICS0 (nM)
inhibitor HXB2 JRFL
PIE12fc 37 ±  2.3 580 ±  21.4
AHP-PIE12 3100 ±  783 nd
Chol-PEGr PIE12 69 ±  11 nd
Chol-PEG12-PIE12 12 ±  3.6 nd
Chol-PEG^-PIEn 0.64 ±  0.25 nd
C34 1.4 ±  0.3 13.4 ±  0.1
C34-PEGr Chol 0.044 ±  0.0004 0.05 ±  0.01
C34-PEGl r Chol 0.021 ±  0.0014 0.024 ±  0.005
C34-PEG80-Chol 0.022 ±  0.0004 0.1 ±  0.045
PEG4-AHP-PIE12-trimer 300 ±  7.2 nd
PEGS-AHP-PIE12-trimer 380 ±  13 nd
PEG4-PIE12-trimer 0.72 ±  0.04 2.1 ±  0.28
Chol-PEG12-PIE12-trimer 0.052 ±  0.02 0.06 ±  0.004
Chol-PEG16-PIE12-trimer 0.02 ±  0.002 0.017 ±  0.0002
Chol-PEG24-PIE12-trimer 0.013 ±  0.0013 0.019 ±  0.003
Chol-PEG36-PIE12-trimer 0.011 ±  0.0015 0.015 ±  0.005
Chol-PEG57-PIE12-trimer 0.007 ±  0.0013 0.013 ±  0.003
Chol-PEG132-PIE12-trimer 0.012 ±  0.0015 0.025 ±  0.002
C8-PIE12-trimer 0.42 ±  0.01 nd
C16-PIE12-trimer 0.09 ±  0.014 0.11 ±  0.012
C18-PIE12-trimer 0.054 ±  0.018 0.087 ±  0.012
“Antiviral potency against HXB2 and JRFL HIV-1 strains. bFrom ref 
21.
original PEGS. To determine whether PEG4 or PEGS was the 
optimal arm length, both PEGS and PEG4 AHP-PIE12 
conjugates were attached to the homotrimeric scaffold, and 
we observed that a PEG4 linker was slightly more optimal 
(Table l). Therefore, PEG4 was selected as the new standard 
linker for conjugating PIE 12 to the scaffold. The scaffold 
synthesis strategy is dramatically simpler than our previous 
method for generating trimer since it requires only one peptide 
and a single purification. Additionally, the yields are 
considerably higher due to the reduced number of purification 
and lyophilization steps that led to loss of active NHS esters in 
the previous strategy. Finally, the high activity of the scaffold 
and single-pot reaction allow for near-stoichiometric concen­
trations of peptide and scaffold, further improving yield.
Heterotetrameric Scaffold. With the optimal PEG linker 
length in place, we next turned our attention to improving 
PIE12-trimer’s potency via localization to sites of viral entry 
(the cell surface). To enable the conjugation of membrane- 
localizing groups to PIE12-trimer, we designed a heterotetra­
meric scaffold containing three short arms with NHS ester 
groups (for addition of PIE12-PEG4-NH2) and a fourth PEG 
arm of variable length functionalized with maleimide (an 
orthogonal reactive group for the addition of thiol-containing 
cargoes) (Figure 2b).
Our first cargo for the heterotetrameric scaffold was 
cholesterol. Several recent studies have shown that cholesterol 
conjugation improves both the potency and the circulating half­
life of C-peptide inhibitors of HIV27 and paramyxoviruses.28’29 
Cholesterol conjugation has also been shown to specifically 
localize dyes to the membrane surface.30,31 A challenge of 
applying this approach to PIE12 is that, while the N-terminus 
of the C-peptide lies immediately adjacent to the membrane, 
PIE12 targets a pocket that we estimate is ~60 A from the 
membrane (Figure l). We used flexible PEG linkers of varying 
lengths to span this distance. PEG12 is sufficiently long if
dx.doi.org/10 .1021/bc300076f I Bioconjugate Chem. 2012, 23, 1252 -1258
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dramatically reduces PIE7-dimer potency.21 Selection of 
resistance to PIE12-trimer required more than a year of viral 
passaging, but ultimately resulted in the Q577R mutation, 
which decreases PIE12-trimer potency by > 1000-fold.21 The 
effect of these resistance mutations on chol- and C16/18- 
PIE12-trimer potency is shown in Table 2. The relative effects
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Table 2. Antiviral Potency against Resistant Strains"
IC50 (nM)
inhibitor WT HXB2 E560K/V570I QS77R
PEG4-PIE12-trimer 0.72 0.89 >3 fiM
Chol-PEG24-PIE12-trimer 0.013 0.01 10.1
C8-PIE12-trimer 0.42 0.86 452
C16-PIE 12-trimer 0.09 0.045 39
C18-PIE 12-trimer 0.054 0.035 32.5
“Antiviral potency against identified resistant strains (HXB2 back­
ground). The ICS0 standard error of the mean values are <35% for all 
samples.
of both resistance mutations are similar for PIE12-trimer and 
the cholesterol/alkane-conjugated PIE12-trimers. However, 
because of the greatly improved potency of the conjugated 
PIE12-trimers, these inhibitors maintain nanomolar potency 
even against the severe Q577R resistance mutation. The impact 
of the less severe E560K/V570I resistance mutation is absorbed 
by all of the conjugated PIE12-trimers, as well as plain PIE12- 
trimer. These data suggest that the improvement in potency 
through C 16/C 18 and cholesterol conjugation retains enough 
excess binding energy to maintain an effective resistance 
capacitor.
■  DISCUSSION
PIE12-trimer, our previously described D-peptide inhibitor, is a 
promising preclinical candidate for the treatment and 
prevention of HIV-1 due to its strong potency, wide breadth, 
and highly charged resistance capacitor that slows the 
emergence of resistance mutations. However, the transient 
nature of PIE12-trimer’s target means that its potency is 
restricted by its diffusion-limited association rate with the gp41 
pocket. In an attempt to break through this potency barrier, we 
designed a heterotetrameric scaffold to allow us to conjugate 
various membrane-localizing cargoes to PIE12-trimer. This 
scaffold also allows us to produce PIE12-trimer variants much 
more efficiently than previously reported. As hoped, con­
jugation of PIE12-trimer to cholesterol or C16/C18 reduces 
the kinetic limitation and greatly improves potency up to 160­
fold.
We hypothesize that this increased potency is due to local 
concentration of inhibitor at membrane sites of viral entry. 
Cholesterol is specifically enriched at sites of viral entry (lipid 
rafts, where CD4 and coreceptor are localized).38’39 The 
mechanism by which cholesterol improves potency is the focus 
of ongoing work. Preliminary evidence suggests that the 
interaction between cholesterol and the membrane is readily 
reversible, which may explain why there is a broad range of 
compatible linker lengths. It may also be the case that 
cholesterol-conjugated inhibitors interact directly with Env, as 
a cholesterol recognition/interaction amino acid consensus 
sequence (CRAC) has been identified in the membrane 
proximal region of gp41.40
By comparison, C16 and C18 conjugates are less potent than 
the cholesterol conjugate. Saturated fatty acids C16:0
(palmitate) and C18:0 (stearate) are also enriched in lipid 
rafts,41 but are abundant in the general plasma membrane as 
well.42 The reduced potency of alkylated PIE12-trimer 
compared to cholesterol may therefore be explained by a 
relatively lower affinity of alkyl chains for lipid rafts. Another 
possible explanation is fatty-acid sequestration by albumin, 
which is known to bind fatty acids with high affinity (compared 
to cholesterol),43 though it is not known how loss of the acid 
group (leaving an alkane chain) affects this binding.
GPI anchors in lipid rafts contain C16 and C18 alkyl chains 
as well as acylated C16 and C18 fatty acids.44 Originally, we 
synthesized alkyl conjugates, and noted that they improved 
potency through membrane association (overcoming the 
potency plateau). For completeness, we also synthesized an 
acylated C16 (fatty acid) conjugate. Surprisingly, the C16 acyl 
conjugate was much less potent than the C16 alkyl conjugate 
(data not shown), presumably because it does not associate as 
effectively with plasma membranes. This finding may explain 
why a recent study did not observe a potency enhancement 
with C16 acylation of C34.27
Importantly, we show that membrane localization does not 
impair the resistance capacitor. Both chol- and C16/C18- 
conjugated PIE12-trimer are able to absorb the affinity- 
disrupting impact of PIE7-dimer resistance mutations 
(E560K/V570I). For the more severe PIE12-trimer resistance 
mutation Q577R, the relative loss of potency for both 
conjugates is comparable to that seen with PIE12-trimer. The 
full resistance profile of these conjugates will be determined by 
ongoing viral passaging studies starting from both wild-type and 
PIE12-trimer resistant virus.
Although PIE12-trimer has ideal antiviral properties, its 
relatively small size (~8 kD) will likely lead to a short serum 
half-life due to renal filtration. In addition to their potency- 
boosting effects, we hypothesize that both cholesterol and alkyl 
conjugation will also lead to improvements in the pharmaco­
kinetic (PK) properties of these inhibitors via interaction with 
cell membranes and albumin that slow renal clearance. Albumin 
serves as a carrier for both cholesterol45 and fatty acids,46 
reducing the rate of renal filtration. Adherence to membrane 
surfaces may also slow the absorption of inhibitor from the 
subcutaneous space, enabling prolonged dosing via a slow- 
release depot effect. This type of depot would be especially 
attractive for nondegradable D-peptides.
This work demonstrates the successful application of 
modular PEG scaffold-based design to peptide drug optimiza­
tion (both peptide geometry and localization to the site of 
action via conjugated localizing cargoes). This approach allows 
for alterations in the scaffold to accommodate a variety of 
cargoes and chemistries (e.g., “click” chemistry), as well as rapid 
optimization of PEG arm lengths. For viruses that undergo 
membrane fusion within the endosome, such as Ebola, this 
strategy could be employed to attach an endosome-targeting 
moiety to localize inhibitor to the site of entry and increase 
potency. Additionally, the scaffold allows for conjugation to a 
variety of cargoes to modulate PK properties (e.g., large 
branched PEGs, albumin, or albumin-binding peptides).47,48 
The scaffold itself is inexpensive to produce and can be used 
directly for cost-effective large-scale production.
PK and animal toxicity studies for chol- and C16/C18- 
PIE12-trimer are underway to determine how conjugation 
alters serum half-life and to determine if any specific toxicity 
arises as a result of conjugation. Fatty acid conjugation has been 
used to prolong serum half-life of a GLP-1 peptide (liraglutide,
dx.do i.org/10.1021/bc300076f I Bioconjugate Chem. 2012, 23, 1252-1258
60
C16) and insulin (detemir, C14). Alkane toxicity in the context 
of peptide conjugates has not been studied.
The in vivo efficacy of these conjugates will be determined in 
future studies of systemic treatment via subcutaneous injection 
or as a vaginally/rectally applied preventative (microbicide) in 
human tissue and animal models. Our D-peptide scaffold is 
especially advantageous for application as a microbicide due to 
its protease resistance, which should enable it to persist for 
extended periods in the vaginal/rectal mucosa’s harsh protease- 
rich environment. The addition of membrane-binding groups 
may also improve microbicide tissue penetration and retention.
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CHAPTER 4
IMPROVING THE PHARMACOKINETICS OF 
D-PEPTIDE HIV-1 ENTRY INHIBITORS
Joseph S. Redman, J. Nicholas Francis, Robert Marquardt, Brett D. Welch,
Alan Mueller, Debra M. Eckert, and Michael S. Kay
Abstract
Unmodified peptides generally have in vivo half-lives on the order of minutes, 
making pharmacokinetic (PK) enhancement necessary. Herein we evaluate several 
strategies for enhancing PK in the context of our lead candidate, PIE12-trimer, a 
protease-resistant D-peptide HIV entry inhibitor. Surprisingly, PIE12-trimer conjugates 
show a general reduction in half-life compared to equivalent monomeric conjugates. 
PEGylation with a 40 kDa Y-branched PEG greatly improves PIE12’s half-life but 
reduces antiviral potency. Moreover, fatty acid conjugation (acylation) and alkane 
conjugation of comparable lengths were found to behave significantly differently. Fatty 
acids failed to improve potency, but reduced the volume of distribution and clearance 6­
fold, while alkane conjugates significantly improved potency with only modest effects on 
half-life. Cholesterol conjugation dramatically improves potency while concurrently
improving half-life. Because of its simultaneous improvements in potency and PK, 
cholesterol conjugated PIE12-trimer is an especially promising therapeutic in the arsenal 
against HIV.
Introduction
Peptide therapeutics are an increasingly important class of medicines. Peptides 
have advantages over small molecules in terms of improved target affinity and 
specificity, as well as an ability to disrupt protein-protein interactions, which are 
generally considered “undruggable” by small molecules1. Furthermore, peptides have 
advantages over proteins in that they can be chemically synthesized, can penetrate deeper 
into tissues, and are generally less immunogenic1.
Despite these advantages, peptide therapeutics face considerable pharmacokinetic 
(PK) challenges. Peptides can be rapidly cleared by the kidneys and degraded by 
proteases, leading to short half-lives. They also do not readily penetrate through cell 
membranes1, limiting access to potential intracellular targets and reducing transcellular 
migration. These same limitations prevent oral administration of peptides such that they 
must be delivered parenterally, usually by subcutaneous (SC) injection. Although 
generally not as preferable as oral delivery, self-administered subcutaneous drugs are 
readily accepted by patients for multiple indications, such as diabetes and HCV.
Recently we reported the development of a highly potent protease-resistant 
D-peptide inhibitor of HIV-1 entry, PIE12-trimer, that exhibits sub-pM binding affinity 
and high pM potency against every major circulating clade of HIV-12,3. Using a 
polyethylene glycol (PEG) scaffold with three arms of discrete length for the attachment
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of PIE12, a peptide composed solely of D-amino acids, synthesis of PIE12-trimer has 
been simplified and yields increased. Moreover, an orthogonally reactive fourth linker 
arm makes conjugation to potency and PK enhancing moieties possible (Figure 4-1).
PIE12-trimer’s target, gp41, is only transiently exposed during HIV fusion. 
Because PIE12-trimer’s off-rate greatly exceeds that time, PIE12-trimer potency is only 
limited by on-rate, which can be increased by membrane-tethering moieties on the fourth- 
arm. Prolonging the off-rate improves affinity for gp41, but not potency. Thus, PIE12- 
trimer binds gp41 with an excess of binding energy. This excess affinity, dubbed the 
“resistance capacitor,” significantly delays the onset of HIV resistance because mutations 
that reduce affinity are still inhibited with equal potency, preventing the stepwise 
accumulation of resistance mutations2. Overall, PIE12-trimer’s broad potency combined 
with its “charged” resistance capacitor provides an ideal preclinical candidate for the 
prevention and treatment of HIV/AIDS.
Ultimately our goal is to develop a weekly or monthly subcutaneous injectable by 
conjugating potency and PK enhancing moieties to PIE12-trimer. For peptides in 
general, PK-enhancing moieties can improve half-life by reducing clearance (e.g., by 
avoiding renal filtration) or sheltering peptides from proteases. As a D-peptide, PIE12- 
trimer is unique because it is already protease stable. Thus, our conjugates will provide 
the first clear view of the pure clearance-reducing potential endowed by a given PK- 
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Figure 4-1. PIE12 and PIE12-trimer Scaffolds with PK-Enhancing Cargoes. PIE12 
is represented by green circles. A) PIE12-trimer, activated PIE12, and activated PIE12- 
trimer are shown schematically (each PIE12 moiety of the PIE12-trimer is linked to the 
scaffold with a discrete PEG4 linker, not shown). B) 40 kDa Y-branched PEG, palmitic 
acid, aliphatic C16 and C18 chains, and cholesterol are conjugated to PIE12 and PIE12- 
trimer by maleimide or NHS-ester chemistry. (modified from2)
Selection of PK-Enhancing Moieties 
When choosing PK-enhancing moieties, we considered both clinically validated 
strategies (such as PEGylation utilized for INF(2a in PEGASYS, and acylation utilized 
for a GLP-1 analogue in Victoza) as well as strategies in preclinical development 
(cholesterol and HSA conjugation)4,5. The benefits and challenges of each strategy are 
described.
PEGylation
PEGylation is a validated strategy for enhancing PK, with eleven FDA-approved 
products. PEG conjugation improves PK primarily by increasing drug size to reduce 
renal filtration, while also decreasing proteolysis and reducing immunogenicity for 
susceptible proteins. The primary challenge of PEGylation is to add enough PEG to 
improve pharmacokinetics without sterically inhibiting the activity of the conjugate. 
Approved PEGylated compounds to date have utilized 20-40 kDa of PEG through single 
or multiple attachments. This amount of PEG is large enough to avoid renal filtration, 
but not too much as to completely inhibit activity or promote uptake into 
reticuloendothelial cells6.
PEGASYS is a particularly well-studied PEGylated protein, and utilizes a single 
branched 40 kDa PEG. Branched PEGs are reported to increase half-life and better 
preserve conjugate activity compared to mass-equivalent straight-chains7. Branched 
PEGs also better protect against proteolysis8. Compared to unconjugated interferon, the
40 kDa branched PEG of PEGASYS prolongs IV half-life in humans from 3.8 to 65 h 
and reduces the volume of distribution 5-fold, thereby slowing clearance 100-fold9 (Table 
4-1). This enhanced PK profile enables once-weekly subcutaneous administration.
Unlike most PEGylated products, however, our peptide is an inhibitor, not a 
hormone or enzyme. Therefore doses must be higher and steadier, so questions regarding 
PEG toxicity become necessary to consider. Fortunately, PEG appears to be remarkably 
nontoxic. For example, the PEG 400 excipient in intravenous (IV) busulfan can be given 
at 300 mmoles (110 g) per week without noticeable toxicity10. With increasing dose, 
eventually PEG toxicity manifests as proximal renal tubule swelling. Recently a patient
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TABLE 4-1. Terminal Half-Lives and Volumes of Distribution for Relevant FDA- 
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C34-HSA ND ND N/A ~1 d28 ~1 d28
Albuferon (INF(2b-HSA) 140 h29
CJC-1131 (maleimide 
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9-15 d29 15-20 h29
was given an average of 650 mmoles (240 g) per week of PEG 400 excipient in IV 
lorazepam for a duration of 43 days. Renal toxicity developed but completely resolved 
upon discontinuation of therapy30. In another report, 32 patients received IV 
nitrofurantoin containing 120-225 g of PEG 300 (~650 mmoles) over 3-5 days. Of these, 
six developed renal toxicity and two died30. It is not clear whether the total mass of PEG 
or molar concentration contributes more to renal toxicity. However, the high molarity 
required to observe toxicity, often in the 10’s of mM, exceeds the dose of current 
PEGylated products by approximately 600-fold10, suggesting general safety of the 
material.
Acylation and Alkylation
PK-enhancement by acylation is based on the strong interaction of fatty acids with 
human serum albumin (HSA), which circulates for 19 days (Table 4-1). A secondary PK 
benefit of acylation is self-association that prolongs absorption from the subcutaneous 
space16,31. Physiologically, free fatty acids (FFAs) circulate bound to HSA, which has 
two high-affinity sites for FFAs and several secondary sites. [Note that “free” means it is 
not esterified to glycerol, and should not be taken to mean it is unbound]. Palmitate (C16 
fatty acid) and stearate (C18 fatty acid) are the predominant forms of circulating FFAs32. 
FFA levels follow a diurnal pattern (rise during an overnight fast) that normally does not 
exceed a 2-fold molar excess over HSA33, although >6-molar excess has been reported in 
diabetic and obese patients34. Circulating FFAs are anionic, although the charge is 
reputed to contribute little to albumin binding35.
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The affinity of HSA for FFAs is in the mid-to-low nM range35-37. Notably, FFAs 
do not bind significantly to any other circulating particles, including low-density 
lipoproteins (LDL)35. Furthermore, FFAs bind sites on HSA that appear to be 
independent of those used by most small molecules. For example, although more than 
98% of circulating myristoylated (C14 fatty acid) insulin detemir is bound to albumin, 
there have been no clinically relevant interactions noted with other protein-bound 
drugs22,35.
Victoza (liraglutide), a GLP-1 analogue, utilizes palmitate conjugation to increase 
its half-life, enabling once-daily subcutaneous dosing. During the development of 
liraglutide, a myriad of other potential PK-enhancing lipids were evaluated17. Notably, 
stearate conjugates had a better half-life but reduced activity, so palmitate was chosen for 
development. Interestingly, liraglutide is not cleared by the kidneys or liver16, consistent 
with its high association with albumin. Apparently the majority of liraglutide is 
catabolized and absorbed by cells.
Based on publications that identify a fatty acid’s aliphatic chain as the critical 
moiety for albumin interaction35, we also explored alkane-conjugation as a substitute for 
acylation. Alkanes only differ from fatty acyl groups by a single terminal carbonyl, and 
thiol-alkanes made synthesis straightforward using the maleimide chemistry of our 
scaffold’s fourth-arm linker.
Cholesterol Conjugation
Cholesterol conjugation of an HIV C-peptide inhibitor improves PK in mice4. As 
a newer strategy for which there are no FDA-approved examples, it is as yet unclear
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exactly how cholesterol improves PK, although we suspect a combination of cell 
membrane and albumin association. Two studies report 435 |iM38 and 24.6 |iM39 
cholesterol affinity for HSA. It is also reported, and consistent with our data, that 
cholesterol provides superior membrane-binding over palmitate4, although this 
interaction is readily reversible2.
HSA Conjugation
Whereas acylation and, likely, cholesterol conjugation improve PK by 
noncovalently interacting with albumin, a direct linkage is reported to improve PK even 
further, consistent with albumin’s long half-life (Table 4-1). Of HSA’s 35 cysteines, only 
one is available for thiol-specific conjugation, Cys-34, found in the Ia subdomain40. 
Importantly, Cys-34 is buried and unavailable for conjugation unless the neighboring 
fatty acid binding site is occupied by fatty acid40. Physiologically, free thiols like Cys-34 
are unusual, prompting the development of in vivo HSA conjugation prodrugs40. Among 
albumin conjugates studied to date, Albiglutide (GLP-1), Albugon (GLP-1), and 
Albuferon (INF(2b) are the most developed5,29,41. An albumin-C34 anti-HIV entry 
inhibitor has also been reported28.
Materials and Methods 
Synthesis of Monomeric PIE12 and Conjugates 
PIE12 was synthesized by RS Synthesis (Loiusville, Ky) using standard solid- 
phase methods. PIE12-PEG12-cholesterol was synthesized by reacting 3 mM PIE12 with 
4 mM maleimide-PEG12-NHS ester (Quanta Biodesign, 10284) in dimethylacetamide
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(DMAC) with 200 mM triethylamine (TEA) for 30 min at RT, then purified by reverse- 
phase HPLC (water/acetonitrile gradient in 0.1% TFA) on a Waters BEH XBridge 10 
p,m, 300 A C18 column (RP-HPLC). The purified product, PIE12-PEG12-maleimide (2 
mM), was reacted with 4 mM thiocholesterol (Sigma-Aldrich, 136115) in DMAC with 
200 mM TEA for 45 min at RT. PIE12-PEG12-palmitate was synthesized by reacting 3 
mM PIE12 with 3 mM Fmoc-N-amido-PEG12-NHS ester (Quanta Biodesign, 10996) in 
DMAC with 200 mM TEA for 30 min at RT, then purified by RP-HPLC. The 
lyophilized product, Fmoc-N-amido-PEG12-PIE12, was dissolved in 20% piperidine in 
DMF to deprotect the terminal amine and repurified by RP-HPLC. The purified product, 
PIE12-PEG12-NH2 (2 mM), was reacted with 4 mM palmitic acid NHS ester (Sigma- 
Aldrich, P1152) in DMAC with 500 mM TEA for 45 min at RT. PIE12-PEG5-40 kDa Y- 
branched PEG was synthesized by reacting 2 mM PIE12 with 20 mM bis-NHS ester 
PEG5 (Quanta Biodesign, 10224) in 100 mM HEPES pH 8.0 for 90 seconds. The 
reaction was quenched in 5% acetic acid and purified by RP-HPLC. The purified 
product, PIE12-PEG5-NHS ester (2 mM), was reacted with 2.5 mM 40 kDa Y branched 
PEG-amine (JenKem, A0010), then purified by RP-HPLC.
Synthesis of PIE12-trimer and PIE12-trimer Conjugates 
PIE12-trimer and PIE12-trimer-PEG24-maleimide were synthesized as previously 
described2. PIE12-trimer C8, C16, C18 and cholesterol conjugates were synthesized by 
reacting 3 mM PIE12-trimer-PEG24-maleimide with 4.5 mM thiocholesterol (Sigma 
Aldrich, 136115), 1-octanethiol (Sigma-Aldrich, 471836), 1-hexadecanethiol (Sigma- 
Aldrich, 52270), or 1-octadecanethiol (Sigma Aldrich, 01858) in DMAC with 200 mM
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TEA for 60 min at RT, then purified by RP-HPLC. Palmitate conjugated PIE12-trimer 
was synthesized by first reacting 3 mM PIE12-trimer-PEG24-maleimide with 4.5 mM D- 
Cysteine in DMAC with 200 mM TEA for 60 min at RT, then purified by RP-HPLC. 
The purified product (2 mM) was reacted with 5 mM palmitic acid NHS ester (Sigma- 
Aldrich, P1152) in DMAC with 500 mM TEA for 45 min at RT then purified by RP- 
HPLC.
Pseudoviral Assay
Pseudovirion infectivity assays were conducted as previously described3,42. 
Briefly, a six-point dilution series of inhibitor was generated in quadruplicate in HOS- 
CD4-CXCR4 (for HXB2) or HOS-CD4-CCR5 (for JRFL) target cell seeded plates, after 
which HXB2 (X4) and JRFL (R5) luciferase reporter psuedovirions were added. After 2 
days, cells were lysed using GloLysis buffer (Promega) and BrightGlo (Promega) 
luciferase reagent was added. Luminescence was read on a PolarStar Optima (BMG) 
plate reader. Counts were normalized to uninhibited controls. Curves were plotted and 
fit to a standard IC50 equation for normalized data [1 -  c/(IC50 + c)], weighting each point 
by its standard error using KaleidaGraph (Synergy software). Reported IC50 values are 
the average of at least two independent assays.
HSA Affinity Studies 
A 4 x 100 mm, 5 |im Chiral-HSA column was generously donated from Chiral 
Technologies Inc. to enable HSA affinity studies. Samples were injected on an Agilent 
HPLC system and eluted isocratically at 0.9 mL/min with 15 mM potassium phosphate
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buffer, pH 7.4 with 7.5% ACN and 7.5% isopropanol at 37 °C. All absorbance traces 
were measured at 214 nm except for warfarin at 308 nm.
Pharmacokinetic Studies 
Animals, Dosing, and Collection
For monomers PIE12, Chol-PIE12 and PEG40-PIE12, PK studies were conducted 
by Invitek. All other studies were conducted by Navigen. Studies were conducted by 
dosing three Sprague Dawley rats (0.22-0.44 kg) for each compound and route (doses 
listed in Table 4-5). Blood samples (~300 |il) were taken over 10 timepoints, 
anticoagulated with lithium heparin. Samples were spun and ~150 ^L plasma was 
collected for quantitation.
LC/MS/MS Quantitation
Drug concentrations in plasma were determined using an AB Sciex API 3000 
triple-quad LC/MS/MS by MRM methods. Standard curves were produced in pooled 
Sprague Dawley rat plasma anticoagulated with lithium heparin (Bioreclamation). 
Plasma samples were prepared for LC/MS/MS by spiking with internal standard followed 
by precipitation 2:1 with 98% acetonitrile (ACN) / 2% formic acid. Supernatants were 
run over a C18 reverse-phase column (Waters, 4.6 x 50 mm, 5 |im, XBridge BEH300) on 
an Agilent HPLC system. Lipid conjugates required lower source temperatures (300 °C 
vs. 500 °C) for best reproducibility. For all studies except PEG40-PIE12 the column was 
regenerated after every group of three rats by running an isocratic gradient of 25% 
ddH2O, 25% MeOH, 25% IPA, and 25% ACN for 30 min. This procedure was found to
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be sufficient for removing retained phospholipids. For PEG40-PIE12, a blank run and 
isocratic wash of 25% ddH2O, 25% MeOH, 25% IPA, and 25% ACN for 5 min were 
required after every sample to prevent carryover.
Determining an appropriate starting ACN concentration was also necessary for 
effective elution. For PIE12 (mass transition 1022.3/180.1), Palm-PIE12 (mass transition 
721.4/282.3), and Chol-PIE12 (mass transition 1066.6/229.1), the starting concentrations 
were 15%, 40%, and 82% ACN, respectively. PEG40-PIE12 was fragmented in the 
source (5000 Volts) and the mass transition monitored was 133.1/89 with a starting 
concentration of 37% ACN. For PIE12-trimer (mass transition 1431.7/180.1), Palm- 
PIE12-trimer (mass transition 1466.5/554.5), C16-PIE12-trimer (mass transition 
1450.1/453.4), C18-PIE12-trimer (mass transition 1454.5/481.3), and Chol-PIE12-trimer 
(mass transition 1474.2/1694.9), the starting concentrations were 35%, 40%, 65%, 65%, 
and 75% ACN, respectively.
Fitting the Data
IV-dosed time-points were plotted and fit to a non-compartmental model to 
determine C0 and the terminal half-life (T1/2) using the equation C(t) = C0*((1/2)(t/T1/2)), 
where C0 represents the theoretical starting concentration if drug were instantly 
distributed (no alpha phase). The terminal half-life is then converted into the decay rate 
ke (ke = ln2/T1/2). SC-dosed time-points were plotted and fit to the model C(t) = 
K*(ka/(ka-ke))*[exp(-ke*t) - exp(-ka*t)], where K is a constant, ka is the rate of 
absorption, and ke is the decay rate determined from the IV fit (weighting to the standard 
deviation of duplicate measurements, KaleidaGraph). Volume of distribution (Vd) is
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determined by dividing dose (in moles) by C0. Because elimination is first order, 
clearance (CL) can be determined by the relationship CL = ((ln2)*(Vd))/(T1/2). Areas 
under the curve (AUCs) were calculated by integrating fits from zero to infinity. 
Bioavailability (F) is determined by F = 100*(AUCSC / AUCiV)*(DoseiV / DoseSc)
Metabolism Studies
PK plasma samples were prepared for pseudoviral assay by 2:1 precipitation with 
98%ACN/2%FA, followed by centrifugation for 10 min in a microcentrifuge at 13,000 
rpm. Supernatants were spun to dryness on speed-vac, followed by resuspension in 50 
mM HEPES pH 7.4 to their original volumes. Pooled plasma was prepared as a control. 
Samples were then diluted 1:10 or 1:100 in DMEM/10% FBS and assessed in a 
pesudoviral assay as described (diluting samples 2-fold further) with normalization for 
uninhibited controls in the presence of prepared control plasma (1:20 prepared plasma 
slightly reduced viral infectivity). A standard IC50 curve was prepared alongside plasma 




Using clinically successful and promising preclinical PK-enhancing moieties, we 
designed and synthesized several PIE12 and PIE12-trimer conjugates (Table 4-2).
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TABLE 4-2. Conjugate Designs and Naming Scheme
Abbreviated name Full name
Monomers
PIE12 PIE12GK












The effects of each conjugation on antiviral potency are shown in Table 4-3. As 
expected, the large 40 kDa Y-branched PEG reduces the potency of our inhibitors, likely 
due to steric interference with target binding. Specifically, the potency of monomeric 
PIE12 is reduced by 2.5- (HxB2) and 10-fold (JRFL), and the potency of PIE12-trimer is 
reduced by 13 (HxB2) and 34-fold (JRFL). In comparison, the same PEG on PEGASYS 
reduces activity 14-fold9.
In contrast, the smaller hydrophobic conjugations mostly increased the potency of 
our inhibitor, but to varying extents, from little or no increase with C8 conjugation to a 2 
log improvement with cholesterol conjugation. The C8 alkane only modestly improves 
potency, while C16 and C18 alkanes improve potency significantly. A C16 fatty acid 
(palmitate) also improves potency, but to a much lesser extent than C16 alkane,
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TABLE 4-3. Potency Effects of PK Conjugation








PIE12 41 37 ± 2.3t 580 ± 21.4t
PEG40-PIE12 47 93 ± 32 5640± 950
Palm-PIE12 67 243 ± 23 1660± 14
Chol-PIE12 88
*







PEG40-PIE12-trimer 47 9.5 ± 1.4 71 ± 12
C8-PIE12-trimer 55
*
0.42 ± 0.01 2 ± 0.58

















suggesting that acyl groups interact with membranes differently than alkanes. 
Cholesterol interacts with membranes even more strongly4, improving potency over other 
lipid conjugates. Notably, cholesterol conjugates remain highly soluble2.
PIE12-trimer conjugations to albumin are still preliminary, but have been 
informative. Using incompletely purified material (approximately 4:1 HSA to HSA- 
PIE12-trimer), there appears to be only a modest five-fold loss in potency compared to 
PIE12-trimer in pseudoviral infectivity assays. However, challenges remain regarding 
complete purification of HSA-PIE12-trimer, and reliable quantitation of HSA-PIE12- 
trimer in plasma samples. Gel filtration is successful at removing unreacted PIE12-
trimer, but does not remove unreacted HSA. Unreacted HSA and HSA-PIE12-trimer 
conjugates can be separated by reverse-phase HPLC, but this process completely 
denatures albumin. It has been reported, however, that not only can HSA be completely 
recovered off a reverse-phase column43, it can also be efficiently refolded following 
HPLC denaturation and lyophilization44,45. Soluble microaggregates, if present, can be 
detected by light scattering44.
HSA Affinity Studies
Acyl and alkane conjugates were synthesized with the intention to improve PK 
through HSA binding. To assess the relative HSA affinities of PIE12 and PIE12-trimer 
conjugates we utilized an immobilized HSA affinity column. Longer retention times on 
this column correlate with higher HSA affinity46 (Table 4-4, Fig. 4-2). Small molecules 
with known affinities for HSA have been included for reference; L-Tryptophan (90.9 |iM 
Kd) and (R)- and (S)-warfarin (4.8 and 3.8 |iM KD respectively)46.
Notably, Chol-PIE12-trimer shows reduced affinity for HSA compared to Palm- 
PIE12-trimer, but comparable affinity to C18-PIE12-trimer. PEG40-PIE12 shows the 
least affinity for HSA. Interestingly, C8-PIE12-trimer, with its long fourth-arm PEG 
linker, shows slightly reduced affinity for HSA compared to the three-armed PIE12- 
trimer, while C16-PIE12-trimer is not so limited.
PK Studies
In order to understand the PK effects of the different PK-enhancing moieties, we 
studied conjugates of both PIE12 monomer as well as PIE12-trimer (our lead anti-HIV
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TABLE 4-4. HSA Affinity Column Retention Times



























Figure 4-2. HSA Affinity Column Retention Times. Compounds are listed in order of 
elution. HEPES buffer from the samples elutes at 1.01 min.
drug candidate). PK studies of C8 conjugates were not pursued due to poor potency 
improvements and low affinity for HSA. Similarly, significant losses in potency for 
PEG40-PIE12-trimer reduced our interest in it as a lead preclinical candidate. Although 
we did not pursue PK studies for PEG40-PIE12-trimer, we did study PEG40-PIE12 to 
assess the general PK-enhancing properties of PEGylation. Representative PK data are 
shown in Figures 4-3 and 4-4, and a summary of PK parameters is given in Tables 4-5 
(IV data) and 4-6 (SC data).
PIE12 has a 1.9 hour IV terminal half-life vs. only 0.54 hours for PIE12-trimer. 
Similarly, Chol-PIE12 and Chol-PIE12-trimer IV terminal half-lives differ by 3-4 fold, 
5.1 hours and 1.6 hours, respectively. Whereas PEG40-PIE12 greatly enhances half-life 
to 26.8 hours, Palm-PIE12 did not affect the terminal half-life compared to PIE12 (1.8 vs. 
1.9 hours, respectively). However, the palmitate moiety did reduce the volume of 
distribution and clearance 6-fold. Palmitate on Palm-PIE12-trimer did improve half-life 
compared to PIE12-trimer (1.5 vs. 0.54 hours, respectively), reduced clearance ~10-fold, 
and reduced volume of distribution ~6-fold.
Notably, identical compounds have different terminal half-lives depending on the 
route of administration, because terminal half-lives are apparent half-lives (a mix of 
absorption from tissue compartments and elimination47). All PIE12-trimer conjugates 
acquired an approximate 2-fold improvement in terminal half-life after subcutaneous 
administration, with the exception of Palm-PIE12-trimer (~1.3-fold improved).
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PIE12 monomer conjugates (IV)
Time (hours)
Figure 4-3. Pharmacokinetics of Four Intravenously Administered Monomers in 
Rats. Data are from single representative animals. Terminal half-life fits are shown, 





Figure 4-4. Pharmacokinetic data of five trimers in rats. A) Intravenously- 
administered trimer data from single animals. Terminal half-life fits are shown, with 
linearity establishing first-order clearance. B) Subcutaneously-administered trimer data 
from single animals. Standard two-phase absorption-elimination fits are shown. Error 
bars are the standard deviation of duplicate measurements.
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TABLE 4-5. IV Pharmacokinetic Parameters of PIE12 and PIE12-trimer 
Conjugates in Rats.___________________ _________ _____________ _________
Inhibitor m.w. Dose Term. T1/2 
(IV)
IV  AUC0 °
(nM *hr)'
Vd (mL) C L
(mL/hour)
Monomers
PIE12 2043.3 1.4 mg/kg 1.9 h 2,891 116 42
PEG40-PIE12 42345.8 0.9 mg/kg* 26.8 h 223,658 20 0.5
Palm-PIE12 2881.6 1.2 mg/kg 1.8 h 15,534 17.5 6.7
Chol-PIE12 3196.9 2.2 mg/kg 5.1 h 26,451 22 3
Trimers
PIE12-trimer 7153.2 1 mg/kg 0.54 h 153 211 271
C16-PIE 12-trimer 8692.2 1 mg/kg 0.65 h 876 37 39
C18-PIE12-trimer 8720.2 1 mg/kg 0.84 h 814 50 41
Palm-PIE12-trimer 8793.3 1.2 mg/kg 1.5 h 1675 42 20
Chol-PIE12-trimer 8835.4 1 mg/kg 1.6 h 2049 38 16
*PIE12 portion of the weight; f  normalized to dose (AUC per mg/kg)
TABLE 4-6. SC Pharmacokinetic Parameters of PIE12-trimer Conjugates in Rats.











PIE12-trimer 1 mg/kg 1 h 0.7 h 451 295 0.84 h 84
C16-PIE 12-trimer 1 mg/kg 1.3 h 0.9 h 936 107 1.1 h 183
C18-PIE12-trimer 1 mg/kg 1.5 h 1.2 h 745 92 1.4 h 187
Palm-PIE12-trimer 1.2 mg/kg 2.1 h 0.5 h 609 36 1.2 h 603
Chol-PIE12-trimer 1 mg/kg 3.4 h 2.7 h 340 17 3 h 146
f  normalized to dose (AUC per mg/kg)
Discussion 
Potency Effects
It is interesting to note that for PIE12-trimer conjugates, elution time off a C18 
reverse-phase column correlates with potency, indicating that potency enhancement is 
directly related to hydrophobicity of the lipid moiety. PIE12-trimer potency is limited by 
on-rate, so improvements in potency likely reflect improvements in membrane binding2. 
This indicates a relationship where the more hydrophobic lipids interact more effectively 
with membranes.
Given the potency increase with palmitate conjugation to PIE12-trimer, it is 
surprising that monomeric PIE12 is not similarly enhanced. Although the PEG12 linker 
between PIE12 and palmitate is shorter than optimal2, the same linker between PIE12 and 
cholesterol still improves potency over PIE12. Considering palmitate’s higher affinity 
for HSA over cholesterol, it is possible that fatty acid conjugates are being sequestered by 
albumin in the assay, and that PIE12-trimer’s branched PEG scaffold prevents 
sequestration in the same manner.
PK Effects
Because of PIE12-trimer’s large volume of distribution and rapid equilibration 
(no alpha phase noted), the resultant low concentrations were near the sensitivity limit of 
our method of quantitation. Reduced accuracy regarding AUC calculations are likely 
responsible for the apparent higher bioavailability of SC vs. IV administered PIE12- 
trimer.
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The difference in subcutaneous half-life between alkylated and acylated 
conjugates (1.3h vs 2.1 hr, respectively, for trimeric inhibitors), which differ only by a 
carbonyl group, is surprising (comparing data for C16 acylation and C16 alkylation). The 
uncharged acyl group reduces hydrophobicity compared to an equivalent alkane, 
lowering membrane affinity and antiviral potency while simultaneously improving 
albumin affinity and half-life. Differences can also be observed in the absorption rate, 
with the more hydrophobic alkanes prolonging absorption from the subcutaneous space. 
Like PEG, acylation reduces the volume of distribution, consistent with albumin binding. 
Compared to Palm-PIE12, Palm-PIE12-trimer has reduced albumin affinity and a larger 
volume of distribution, suggesting the PEG scaffold may be interfering with beneficial 
HSA interactions.
Half-life comparisons between related PIE12 and PIE12-trimer conjugates are 
also surprising. While originally we assumed that increasing molecular weight from a 
monomer to a trimer could only improve half-life by reducing renal filtration, there is 
actually an across-the-board 3-5 fold faster clearance for each PIE12-trimer conjugate. 
Conjugations to PIE12 monomer improve PK consistent with the literature; PEGylation 
increases half-life to 26 hrs (compared to 15 hrs for PEGASYS8), acylation reduces the 
volume of distribution and clearance 6-fold (despite no apparent change in half-life), and 
cholesterol conjugation increases half-life to 5.1 hrs in rat (comparable to 3 hrs for C34- 
Chol in mice4). Notably, for PIE12-trimer the rank order of PK-enhancement is still 
retained for each moiety, as is the magnitude of improvements endowed by each 
conjugate. Therefore something specific to PIE12-trimer itself must be reducing its half­
life.
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There are indications that PIE12-trimer’s PEG scaffold may be restricting 
beneficial interactions between PK-enhancing moieties and HSA and cell membranes. 
PIE12-trimer conjugates show reduced affinity for HSA and C18 on reverse-phase 
columns compared to monomer equivalents (Tables 4-3 and 4-4, Figure 4-2). 
Furthermore, a C8 alkane conjugated to the long PEG fourth-arm scaffold demonstrates 
even less affinity for HSA than regular PIE12-trimer. Volumes of distribution are also 
greater for PIE12-trimer conjugates compared to monomers, consistent with reduced 
albumin binding. Finally, palmitate conjugation improves PIE12-trimer potency while 
reducing PIE12 potency; the finding might be explained by significant HSA sequestration 
for Palm-PIE12, but less HSA interaction for Palm-PIE12-trimer.
Of the affinity-boosting conjugates, cholesterol produces the best terminal half­
life. Cholesterol interacts more weakly with HSA than palmitate, so the enhanced 
retention is likely due to superior membrane binding. This explanation is also consistent 
with the prolonged absorption rate of Chol-PIE12-trimer from the subcutaneous space 
(2.7 hr half-life). Cholesterol also reduces the volume of distribution like acylation. 
However, the cholesterol moiety may be causing sequestration of Chol-PIE12-trimer. 
The bioavailability of SC-administered Chol-PIE12-timer is only ~20%, suggesting that 
long durations of exposure to cell surfaces may lead to cell surface sequestration, 
endocytosis, or local metabolism. The cholesterol moiety might also direct clearance to 
the liver through LDL binding. It is known that siRNA-cholesterol conjugates, even pre­
bound to HDL or albumin, are redistributed and taken up into LDL particles in mice48, 
and humans circulate significantly more LDL than rodents49. This disparity may change 
the pharmacokinetics of cholesterol conjugates in humans. Animal models with more
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human-like lipid profiles (e.g., Guinea pig, Golden Syrian hamsters, and the LDLR-/- 
mouse)49-51 could provide some insight on in vivo kinetics in the context of increased 
circulating LDL concentrations, and may more accurately predict PK in humans.
In the end, the best clinical candidate must balance potency with 
pharmacokinetics. Although PEGylation yields the greatest PK enhancement, potency 
suffers. Palmitate conjugation improves half-life and potency modestly, but to a lesser 
extent than cholesterol. Alkane conjugation improves potency but does little to improve 
half-life. Of unknown significance is the decreased volume of distribution created by 
each conjugation because it is not clear which tissue compartments must be accessed for 
successful inhibition of HIV transmission. However, it is clear that Fuzeon is highly 
HSA-bound24, has a reduced volume of distribution in humans (Table 4-1), and 
successfully inhibits HIV. Taken as a whole, Chol-PIE12-trimer has become our lead 
candidate for future studies.
Metabolism Studies
We envision four possibilities to explain the enhanced clearance of PIE12-trimer 
conjugates. Reduced affinity for membranes and albumin is the simplest explanation. 
However, enzyme modifications, breakdown, and sequestration are also possible.
To rule out enzyme modification we developed a method to determine the 
concentration of active compound in plasma samples using our pseudovirus infectivity 
assay. We reasoned that although molecular weight-shifted metabolites may be missed 
by LC/MS/MS analysis, it is unlikely that such metabolites would lose antiviral potency, 
especially given PIE12-trimer’s charged resistance capacitor. We analyzed C18-PIE12-
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trimer because it was the first to reveal a surprisingly low terminal half-life by 
LC/MS/MS. C18-PIE12-trimer concentrations calculated from the antiviral activity of 
plasma samples agree with the LC/MS/MS values, indicating that there were no 
detectable active metabolites in the plasma being missed by LC/MS/MS. Therefore, if 
drug clearance is due to a metabolic process, the metabolites must have greatly reduced 
antiviral activity. Notably, PIE12-trimer is stable in rat plasma, even after weeks of 
incubation at 37 °C. Chol-PIE12-trimer is also quite stable in rat plasma, although ~20% 
becomes oxidized (+16 Daltons) after 24 hrs.
We are also pursuing additional methods to discover metabolites. For instance, 
all PIE12-containing analytes produce an acetylated histidine (mw 180.1) daughter ion 
with 5% efficiency. After acetonitrile crash of plasma, the “Precursor Ion” mode on the 
LC/MS can detect metabolites that produce that daughter ion with a ~1 |iM sensitivity 
limit. The sensitivity could be improved with better cleanup of the sample, so we also 
plan to utilize affinity purification with IZN17. IZN17 binds PIE12 and PIE12-trimer 
with 20 nM and sub-pM affinity, respectively. By adding it to plasma samples, all 
PIE12-containing molecules could be selectively purified. These cleaner samples should 
enable sensitive identification of metabolites.
Future Directions
Future studies will include a pilot efficacy study in SHIV-infected macaques in 
order to demonstrate the pharmacokinetics and viral response to unmodified and 
cholesterol-conjugated PIE12-trimer. Suppression of viral load would indicate successful 
exposure and efficacy of our D-peptide antivirals in vivo. To rule out nonspecific
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mechanisms of viral clearance, treatment will be halted after one month to demonstrate 
viral rebound. Treated animals will be compared to infected but untreated control 
animals to verify that the reduced viral load, and subsequent rebound, are specific to 
treatment with inhibitor.
Dose-escalation studies in rats are also planned. We would like to assess how PK 
is affected by changes in stock concentrations (e.g., by creating local depots of self­
associated peptide) and total mass delivered. Moreover, these high-dose studies should 
enable investigation into the clearance mechanism(s) of PIE12-trimer and conjugates. 
Urine, feces, and bile will be collected to determine the roles of renal filtration and biliary 
excretion.
Next, we plan to track fluorescently labeled PIE12-trimer conjugates in vivo (in 
rodents) to better understand clearance, volumes of distribution, and possible sites of 
sequestration. A companion PK study will be done to control for possible PK changes 
created by the fluorescent moiety. This in vivo study will help reveal routes of 
elimination and assess access to different tissue compartments (e.g., lymphatic tissue, 
brain, etc.).
Further, the protease-resistant design of PIE12-trimer enables novel applications. 
For instance, PIE12-trimer is a promising microbicide candidate (antiviral prophylactic) 
because it can withstand the protease-rich environment of the vaginal mucosa. Moreover, 
our several lipid conjugations may enhance PIE12-trimer exposure by augmenting cell 
surface binding. Oral bioavailability may also be possible. By surviving gut proteases, 
PIE12-trimer might be formulated with a gut permeabilizing agent to achieve significant
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circulating concentrations. Promising gut permeabilizers have been extensively 
reviewed52,53.
Finally, sustained delivery technologies may also be readily compatible with 
PIE12-trimer and its conjugates. Microsphere delivery like that utilized by the recently 
approved Bydureon (once-weekly extended release exenatide) may enable a similarly 
favorable dosing schedule for PIE12-trimer.
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INTRODUCTION
n drug discovery and development, peptide therapeutics 
have many advantages. Their polymeric nature makes 
synthesis straightforward, especially when compared 
with the synthetic schemes typically utilized for small 
molecules. Peptides are generally easier and less expensive 
to produce than recombinant proteins. Peptide therapeutics 
can also be more specific (and less toxic) than small mole­
cules and excel at the challenging problem of disrupting large 
protein-protein interaction interfaces (i.e., “undruggable” 
targets). Due to advancements in genomics and proteomics, 
a plethora of natural peptide ligand sequences for important 
drug targets are available and provide a sensible starting 
point for the rational development of therapeutic com­
pounds. In addition, a host of mature and emerging library- 
based screening techniques provides a means to rapidly dis­
cover novel peptide sequences with specific binding proper­
ties.
Despite these enticing advantages, a major problem limit­
ing development of peptide therapeutics is their proteolytic 
sensitivity and associated delivery challenges. Synthetic thera­
peutic peptides are typically relatively unstructured and are 
therefore rapidly degraded in vivo, often with half-lives on 
the order of minutes.1 Proteolysis commonly occurs in the 
GI lumen, intestinal brush border, enterocytes, hepatocytes, 
antigen-presenting cells, and plasma. Because of this in vivo 
fragility, oral delivery is generally not possible, necessitating 
frequent dosing by injection. Even when delivered parenter­
ally, degradation in the blood combined with rapid renal fil­
tration often results in drugs that are expensive, inconven­
ient, and unpleasant to administer.
Protease-resistant peptides would address many of these 
limitations. One of the most promising approaches is to 
modify the chemical structure of the peptide backbone (pep­
tidomimetics).2 Modifications that have been shown to sub­
stantially decrease proteolysis include N-methylation, ester
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linkages (a-hydroxy acids), insertion of additional methylene 
groups into the backbone (/5-amino acids, y-amino acids 
etc.), and the use of D-amino acids. More significant changes 
to the peptide backbone include peptoids, azapeptides, 
oligoureas, arylamides, and oligohydrazides.2-4
In this review, we describe how modified peptide back­
bones can be used to design protease-resistant inhibitors 
with a special focus on the high-priority problem of design­
ing protease-resistant HIV entry inhibitors. Although these 
modified backbones effectively address protease sensitivity, 
each is associated with a set of design challenges using 
rational design or library screening techniques. This review 
will not cover traditional strategies to reduce protease sensi­
tivity, e.g., peptide capping, sequence alteration at susceptible 
sites, cyclization, or stapling, which have been extensively 
reviewed elsewhere.5
INHIBITING HIV ENTRY
An estimated 34 million people worldwide are infected with 
HIV, the causative agent of AIDS, resulting in nearly 2 mil­
lion deaths per year and over 25 million cumulative deaths 
(UNAIDS). Dramatic progress has been made in reducing 
mortality since the inception of antiretroviral therapy against 
HIV enzymes reverse transcriptase, protease, and recently 
integrase. However, the relentless development of drug resist­
ance necessitates ongoing development of therapeutics that 
target other stages in the viral lifecycle. In particular, there 
have been extensive efforts to develop potent, broadly active, 
and economical entry inhibitors for the prevention and treat­
ment of HIV/AIDS.6
The current HIV entry pathway model is shown in Figure 1. 
Viral entry into host cells is mediated by the trimeric HIV en­
velope (Env) glycoprotein. Env contains the noncovalently 
associated surface gpl20 and transmembrane gp41 subunits. 
gpl20’s primary function is to interact with cell receptors that 
mark HIV’s preferred target cells (e.g., T-cells and macro­
phages), while gp41 induces membrane fusion. Host cell inter­
actions are mediated by gpl20 through association with the 
primary cell receptor (CD4) and chemokine coreceptor (either 
CXCR4 or CCR5, depending on viral tropism). Upon gpl20 
engagement with cell receptors, a complex series of structural 
rearrangements in gpl20 propagate to gp41, activating it for 
membrane fusion (reviewed by Ref. 7). At this stage, gp41 
forms an extended prehairpin intermediate containing an 
N-terminal trimeric coiled coil (N-trimer) and C-terminal 
region (C-peptides) of unknown structure. Fusion is driven by 
collapse of this intermediate as three helical C-peptides pack 
anti-parallel to the N-trimer (trimer-of-hairpins formation), 







FIGURE 1 HIV entry pathway. HIV Env is composed of surface 
(gpl20, green) and transmembrane (gp41, blue) subunits. Fusion is 
initiated by binding to CD4 and a chemokine coreceptor, which 
activates gp41 and induces formation of the prehairpin intermedi­
ate. In this intermediate, the gp41 N-terminal region forms a tri­
meric coiled coil (N-trimer, gray), which is separated from the C- 
peptide region (dark blue). This intermediate slowly collapses to 
form a trimer-of-hairpins structure that brings the viral and cell 
membranes into close apposition, leading to fusion. C-peptide and 
D-peptide inhibitors bind to the N-trimer, preventing trimer-of- 
hairpins formation and membrane fusion.
A similar fusion mechanism is utilized by many other enveloped 
viruses, including influenza, Ebola, and paramyxoviruses.
C-Peptide Inhibitors
This mechanism suggests that peptides derived from the 
N- and C-peptide regions of gp41 could prevent viral mem­
brane fusion in a dominant-negative manner by preventing 
trimer-of-hairpins formation. Indeed, both N-and C-pep­
tides inhibit HIV entry.8-14 The N-trimer/C-peptide interac­
tion is predominantly mediated by conserved interactions 
between the hydrophobic face of helical C-peptides and a 
hydrophobic groove formed between helices in the N-trimer. 
C-peptide inhibitors are more promising drug candidates 
because of their higher potency and better solubility com­
pared with N-peptide inhibitors.
C-peptide inhibitors were first identified through screens 
of gp41-derived peptides.9,11 Fuzeon (Enfuvirtide, T-20) is a 
36 amino acid i-peptide taken from the gp41 C-peptide 
region. Fuzeon inhibits HIV entry with nM potency and 
reduces viral loads by 2 logs,15 leading to its approval as the 
first HIV entry inhibitor in 2003. Unfortunately, Fuzeon’s 
clinical use has been limited by its short half-life. Fuzeon 
requires injection at very high doses (90 mg, twice daily) to 
overcome its proteolysis and rapid renal filtration. These 
practical problems result in a drug that is expensive 
(~  $30,000 per year), can cause painful injection site reac­
tions, and is only approved for patients experiencing treat­
AFIGURE 2 One pocket, two binding solutions, 
with (A) the natural gp41 C-peptide (pdb code 
Structures were aligned on the 17 pocket-forming
ment failure due to multi-drug resistance (“salvage therapy”). 
Fuzeon’s high dosing requirements and in vivo fragility also 
limit options for less frequent dosing via depot formulation.
The gp41 “Pocket” Region
At the N-trimer’s C-terminus lie three symmetry-related 
deep hydrophobic pockets. Each pocket has a volume of 
~400 A3 that is filled primarily by three C-peptide residues 
(Trp628, Trp631, and Ile635)16,17 (Figure 2). The pocket is a 
promising inhibitory target because of its critical importance 
in membrane fusion and very high level of conservation 
across diverse HIV strains.16,18 Mutations in the pocket are 
often not well tolerated due to the requirement for compen­
satory mutations in the C-peptide region to restore binding. 
In addition, the pocket region is encoded by the structured 
RNA region of the Rev-responsive element (RRE), which 
contains a signal critical for nuclear export of viral RNA.18 
Interestingly, extensive efforts by numerous groups to dis­
cover small molecule pocket-binding inhibitors have had 
limited success, generally producing inhibitors with modest 
potency and/or significant toxicity.19-23 Based on this body 
of work, the gp41 pocket appears to be “undruggable” by 
small molecule inhibitors, a common problem for extended 
protein-protein interaction interfaces.
Fuzeon was discovered before the gp41 6-helix bundle 
crystal structure and does not bind to the gp41 pocket. How­
ever, next generation C-peptide inhibitors (e.g., C34, T-1249) 
do include pocket-binding residues and enjoy superior
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The gp41 pocket (from pdb code 3L35) is shown 
1AIK) and (B) D-peptide PIE12 (pdb code 3L35). 
residues from gp41 and rendered using Pymol.
potencies and resistance profiles.24-26 The follow-on com­
pound to Fuzeon, T-1249, performed very well in clinical tri­
als, but was not developed further due to unspecified formu­
lation problems, which we speculate includes challenges in 
the economic synthesis of this 39-residue peptide and a 
requirement for four 1 mL injections, once per day, as used 
in a phase I/II trial.25
Fuzeon and T-1249 show that a peptide fusion inhibitor 
can be very effective against HIV, but the impact of such 
drugs will be limited until the problems of short half-life and 
high dosing (and the resulting high cost) can be overcome. 
In this review, we focus on two distinct strategies that have 
yielded promising protease-resistant peptide fusion inhibi­
tors with the potential to overcome Fuzeon’s in vivo fragility.
RATIONAL DRUG DESIGN WITH MODIFIED 
PEPTIDE BACKBONES
While there is much interest in the de novo development of 
peptides with defined structural and functional characteris­
tics, this work is hampered by limitations in currently avail­
able modeling strategies. Thus, as illustrated below, most suc­
cessful rational designs of protease-resistant peptides start 
from sequence and structural information from existing pep­
tide ligands.
In the realm of rational design of modified peptide thera­
peutics, /(-peptides and mixed a/jS-peptides are among the 
most promising, /(-peptides are composed of /(-amino acids, 
which contain an extra backbone methylene group (between
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FIGURE 3 Peptidomimetic structures.
the amino and a-carbon, specified as a p 2-amino acid, or 
between the carboxylate and a-carbon, specified as a 
/j3-amino acid) (Figure 3). Short /i-peptide sequences can 
adopt robust secondary structures analogous to a-helices 
formed by a-amino acids. If a natural helical peptide ligand 
is known, a /i-peptide mimic can be generated by the precise 
placement in three dimensions of key side chains onto a 
/i-peptide scaffold. TVo /i-peptide scaffolds that have been 
extensively utilized are the 12-helix and 14-helix, named after 
the number of atoms between hydrogen bonding groups 
(these and other ^-residue-containing scaffolds are reviewed 
elsewhere3,27-30). The specific structural motif adopted by a 
particular /i-peptide is dictated by the nature of the substitu­
ent /5-amino acids.31 /i-peptides composed of monosubsti­
tuted, acyclic /i-amino acids or cyclic six-member ring 
/i-amino acids preferentially adopt the 14-helix structure, 
while the 12-helix structure is favored by peptides composed 
of cyclic five-member ring /i-amino acids. The helical param­
eters of the 12- and 14-helices are discussed and compared 
with a-helices in Refs. 27 and 31.
In a 14-helix composed of /?3-amino acids, side chains at 
residues i, i+3, and i+ 6 are presented along the same face of 
the helix, and are reasonably superimposable with side chains 
at residues i, i+4, and i+7 of an a-helix.32 This property can 
be exploited to display epitopes that mimic an a-helical face 
and has been applied to the development of low-mid /jM
HIV entry inhibitors that bind to the gp41 pocket region.33,34 
In an analogous approach, /i-peptide inhibitors of HCMV 
entry were developed using the 12-helix scaffold.35 To map 
an a-helix epitope onto the 12-helix, side chains at positions 
i, i+4, and i+7 on the a-helix are placed at positions i, i+3, 
and t+5 on the 12-helix. Although acyclic residues dimmish 
12-helix propensity, they provide the easiest avenue for side 
chain attachment, so a minimum number of acyclic ft2 or /i3 
residues were introduced into the structure at specific points 
to mimic side chain presentation of the native a-helix. This 
approach enabled the rapid discovery of inhibitors with 
modest potency, but its main challenge is the lack of a route 
forward, by rational design or high-throughput screening, to 
optimize these initial hits.
A sequence-based approach utilizing mixed a//i-peptides 
has been applied to develop an HIV entry inhibitor that 
structurally and functionally mimics C-peptides (~ 1 0  turn 
a-helix).36 In this approach, a subset of C-peptide residues 
were strategically replaced with homologous /?3-amino acids 
following an aa/iaaa/J pattern, which, despite the additional 
methylene units, does not significantly alter secondary struc­
ture of the helix.37 On folding, this pattern generates an a- 
helix-like conformation with a /J-residue stripe that runs 
down the side of the helix distal to the interaction surface, 
minimizing disruption of the binding interface. On replacing 
11 of the 38 residues with /?3-amino acids, the resulting a//J- 
peptide had >10,000-fold diminished affinity for its binding 
target relative to the a-peptide counterpart.
As a second step in the design, specific /i3-residues were 
replaced by cyclic ^-residue homologues. The cyclic residues 
were incorporated to reduce the entropic penalty associated 
with helix formation due to the inherent torsional flexibility 
of /?3-residues. /?3 analogues of alanine in the a//i-peptide 
were replaced with a nonpolar, five-member ring constrained 
^-residue (ACPC), while /i3 analogues of arginine were 
replaced with a polar, heterocyclic analogue of ACPC (APC). 
These replacements improved affinity by ~  400-fold over the 
peptide with acyclic residues. Although the binding affinity 
never recovers to that of the original a-peptide ligand, the 
resulting a//i-peptide was nearly as potent as the a-peptide, 
but with the added advantage of being 280-fold more resist­
ant to proteolytic degradation by proteinase K. The apparent 
discrepancy of having diminished binding affinity, yet a-pep- 
tide-like potency is likely due to the potency plateau 
observed for many HIV entry inhibitors (see the discussion 
of the “resistance capacitor” below).
The original report indicated that the N-terminal Trp- 
Trp-Ile motif of the a//i-peptide does not engage the C-ter­
minal hydrophobic pocket of gp41, but subsequent crystallo- 
graphic analysis indicated that that the pocket-binding motif
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on the a/jS-peptide is indeed able to engage the pocket. The 
authors suggest that the lack of engagement in the original 
structure was an artifact caused by crystal packing, and that 
the newer structure more faithfully portrays the binding of 
the a//i-peptide (see discussion in supplementary materials 
of Ref. 38).
GENETICALLY ENCODED LIBRARY-BASED 
SCREENS
An alternative to rational design is screening of random pep­
tide libraries. These high-throughput methods identify novel 
peptides with a desired function (typically binding to an im­
mobilized target). Commonly used screening techniques 
include phage, ribosome, and mRNA display, but these 
methods all rely on cellular translation machinery and are 
therefore not yet fully compatible with peptidomimetics in 
their standard forms. Though there have been many advan­
ces and refinements in the field of synthetic peptidomimetic 
library generation (e.g., split and pool synthesis, physically 
addressable synthesis by photolithography), these synthetic 
libraries are typically limited to <106 members39 compared 
with the billion to trillion member libraries that can be gen­
erated with genetically encoded libraries.
D -Peptides
D-peptides are entirely composed of D-amino acids, which 
are mirror-image stereoisomers of the L-amino acids found 
in naturally occurring L-peptides. D-Peptides are a promising 
therapeutic platform because they are highly resistant to nat­
ural proteases.40 In elegant work by the Kent group,41 D-HIV 
protease was shown to cleave only D-peptide substrates, 
showing that proteases exhibit highly stereospecific substrate 
discrimination.
The symmetry relationship between l- and D-peptides can 
be exploited in mirror-image display techniques42 in which a 
mirror-image version of the target molecule is generated by 
solid-phase synthesis using D-amino acids. Randomized ge­
netically encoded L-peptide libraries are then screened against 
this D-target. The winning L-peptides are identified by DNA 
sequencing and then the corresponding D-peptides are syn­
thesized. By symmetry, the D-peptide will have the same ac­
tivity toward the natural L-target as the L-peptide had against 
the mirror-image D-target (Figure 4).
A major limitation of mirror-image display is the require­
ment for chemical synthesis of the D-target. Synthesis of d- 
peptides is currently done using traditional solid phase pep­
tide synthesis (SPPS).43 Routine use of SPPS chemistries for 
the production of peptides is limited to ~50 residues,
FIGURE 4 Mirror-image phage display. Phage bearing L-peptides 
are panned against a mirror-image protein (D-target). By symmetry, 
D-versions of binding peptides will bind to the natural L-targets.
though this limit varies widely depending on the required 
purity and sequence/structure properties of the peptide in 
question (e.g., extended beta-strand peptides can aggregate 
during SPPS). Despite these challenges, syntheses of very 
long peptides have been reported (e.g., the synthesis of the 
140-residue IL-3 protein44).
Larger D-peptide targets can be obtained using peptide li­
gation techniques to link multiple synthesized peptide frag­
ments. A variety of ligation chemistries have been developed 
(see Ref. 45 for a very thorough review), but the most com­
mon technique is cysteine-mediated native chemical ligation 
(NCL). NCL requires the presence of an N-terminal cysteine 
on one peptide fragment and a C-terminal thioester on the 
other (see Ref. 46 for a summary of popular recombinant 
and synthetic methods for the generation of peptides bearing 
a C-terminal thioester) and results in the ligation of the two 
segments via a native peptide bond. SPPS of thioester-con- 
taining peptides has traditionally been carried out via Boc 
chemistry, but recent advances have enabled the robust syn­
thesis of thioesters using the easier and more popular Fmoc 
chemistry47 and commercially available Dawson Dbz resin 
(Novabiochem). Other means of accessing peptide thioesters 
via Fmoc chemistry have been recently reviewed.48
By strategically utilizing masked N-terminal cysteines 
(e.g., thioproline), multiple peptide fragments can be joined 
together sequentially or in a single-pot reaction.49-53 This 
strategy has been used in the D-peptide synthesis of the 81- 
residue snow flea antifreeze protein.54 NCL leaves a Cys resi­
due at each ligation site, but this “scar” can be removed by 
desulphurization of the cysteine residue to alanine.55,56 Fur­
thermore, several creative adaptions of NCL allow residues 
other than an N-terminal cysteine to be present at the liga­
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tion junction, such as N-terminal, thiol-containing auxiliary 
groups that can be removed via reduction,57 UV irradia­
tion,58’39 or treatment with acid60'61 after they have facilitated 
peptide bond formation. In another approach, modified ver­
sions of phenylalanine,62 valine,63 or lysine64 bearing a thiol 
substituent were incorporated at the N-terminus of a peptide 
fragment and yielded the respective native amino acid at the 
ligation site following NCL/desulfurization.
Once a D-target has been synthesized, it can be used in 
conjunction with mirror-image display to screen peptide 
libraries for novel sequences of interest (see our work on 
HIV below and Ref. 65). The unifying feature that underlies 
all of the library-based display techniques discussed here is 
the physical linkage of a peptide to its corresponding geno­
type (RNA or DNA). This linkage allows the library to be 
subjected to multiple rounds of interrogation/library amplifi­
cation leading to enrichment of sequences that bind to a tar­
get of interest. In these techniques, library diversity is gener­
ated in the nucleotide coding sequence, and cellular machin­
ery efficiently translates this information into a peptide 
library. The display techniques most suitable for screening 
high-diversity libraries can be broken down into two broad 
categories: viral display and cell-free display systems 
(briefly described here, but for a more extensive review see 
Refs. 66-70).
Viral Display
Phage display continues to be the workhorse of the viral dis­
play techniques because of its ease of use, versatility, and low 
cost. Since phage display requires a bacterial transformation 
step, library size is typically limited to ~  109-1 0 10. The most 
commonly utilized phage display system is the nonlytic M13- 
family filamentous phage, in which the peptide library is 
expressed as an N-terminal fusion with the pill minor coat 
protein. Up to five copies of pill are present on the phage 
surface, making both polyvalent and monovalent display 
techniques possible. Polyvalent display provides a strong 
avidity effect, which is highly advantageous for screening na­
ive peptide libraries containing only rare low affinity binders. 
In contrast, monovalent display reduces avidity and allows 
for more stringent selection of peptides with high affinity. In 
an early round of phage display, library diversity is high, but 
each sequence is represented by only a few phage. As with 
any library display method, the application of selection pres­
sure must be sufficient to drive selection for tighter binders, 
but not so severe as to eliminate rare tight binding sequences 
due to stochastic factors. In later rounds, as phage library di­
versity drops and each remaining sequence is represented by 
numerous phage, selection pressure can be steadily increased.
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Insufficient selection pressure can select for “cheater” phage 
that do not bear authentic tight binding peptides (e.g., phage 
with growth advantages).
Besides filamentous phage display, techniques employing 
various eukaryotic viruses, including retroviruses, baculovi- 
rus, Adeno-associated virus, and Adenovirus have been or 
are currently being developed for displaying peptide libra­
ries.67 Other display techniques (e.g., bacterial, yeast, or 
mammalian cell display) have several advantages over phage 
display (e.g., more sophisticated folding machinery, post- 
translational modifications, ability to use FACS sorting), but 
are more complex and typically limited to less diverse libra­
ries (reviewed by Refs. 66, 67, 71, 72).
Cell-Free Display
One of the major advantages of cell-free techniques (reviewed 
by Ref. 73) is that they are carried out in vitro. Because a 
transformation step is not required, library diversities >1012 
can be generated.69 Due to the proposed correlation between 
library diversity and the affinity of selected ligands, this large 
increase in library diversity over typical viral or cell surface 
display systems provides a distinct advantage.
Ribosome display74,75 capitalizes on the fact that it is pos­
sible to stall the in vitro translation of a polypeptide so that 
the ribosome remains assembled and attached to the mRNA 
transcript and the nascent translated polypeptide. This 
mRNA-ribosome-polypeptide ternary complex serves to link 
genotype to phenotype and can be panned against a target to 
isolate sequences of interest. The ternary complex can then 
be eluted and dissociated with EDTA, allowing for the isola­
tion of the original mRNA transcript.
Alternatively, RNA display76 links phenotype to genotype 
by connecting an mRNA sequence directly to the peptide it 
encodes. This linkage is accomplished by chemically attach­
ing the antibiotic puromycin to the 3’ end of the RNA via a 
DNA linker. As the mRNA is being translated, the ribosome 
will stall once it reaches the DNA linker, allowing puromycin 
to enter the ribosomal A site, where the ribosome catalyzes 
covalent attachment to the recendy translated polypeptide. 
This peptide-RNA complex can then be subjected to panning 
against a specific target.
While in vitro display techniques that link the peptide 
phenotype to an RNA genotype overcome many of the limi­
tations of phage display, the instability of RNA molecules 
along with other technical challenges fundamental to these 
techniques has limited their application to a relatively small 
number of expert laboratories. To address these challenges, 
techniques that link the library peptides directly to their 
encoding DNA have recently been developed.
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CIS display (Isogenica) exploits the unique activity of 
RepA, a bacterial plasmid DNA-replication initiation pro­
tein.77 RepA is a cis-acting protein that tightly binds to the 
origin of replication (ori) on the plasmid from which it was 
expressed. A stretch of DNA between the sequence that enco­
des RepA and the ori known as the CIS element contains a 
rho-dependent transcriptional terminator that is thought to 
stall the RNA polymerase during transcription of RepA. The 
current model holds that this delay allows the newly synthe­
sized RepA protein emerging from the ribosome to interact 
with the CIS element, which subsequently directs RepA to 
the ori DNA. Peptide libraries can be fused to the N-terminus 
of RepA, thereby creating a link between phenotype and the 
DNA genotype. Like other in vitro techniques, CIS display 
has the capability to accommodate peptide libraries much 
larger than those possible for phage display. In one exam­
ple,77 a library of >1012 randomized 18-mer peptides was 
constructed and was used to isolate sequences that bound to 
disparate targets. In a similar approach, DNA sequences 
encoding randomized peptide libraries are fused to the bacte­
riophage P2A gene. P2A is an endonuclease involved in the 
rolling circle replication of bacteriophage P2 DNA. P2A 
becomes covalently attached to the same DNA molecule 
from which it was expressed, linking phenotype to genotype. 
This technique has been used in a pilot study to select single­
chain antibodies from a 107-member library and may be suit­
able for screening much larger libraries.78
d-p e p t id e  in h ib it o r s  o f  h iv  e n t r y
Here we describe the history of our potent D-peptide inhibi­
tors of HIV entry, developed in the Kim and Kay laboratories. 
Initially, mirror-image polyvalent phage display was used to 
screen naive peptide libraries of various lengths and geome­
tries for binding to an HIV N-trimer pocket mimic 
(IQN17).18 Pocket-specific binding was only observed in di­
sulfide-constrained 10-mer sequences (CX10C) containing an 
EWXWL consensus sequence. An initial group of ~  10 win­
ning sequences were validated by measuring their binding to 
the desired target and several negative control targets 
(mutated or missing pockets) to demonstrate pocket-specific 
binding.
Validated D-peptides inhibited HIV entry (lab strain 
HXB2) with IC50 values ranging from 11 to 270 fiM .ls A co­
crystal structure of one of the higher affinity D-peptides 
(DIO-pl) in complex with IQN17 shows that DIO-pl con­
tains two short left handed a-helical segments flanking a turn 
imposed by the disulfide constraint. The binding interface 
between the hydrophobic pocket of IQN17 and DIO-pl is 
mediated by residues in the C-terminal a-helix, with residues
in the EWXWL consensus motif making the largest contribu­
tions. Comparison of the D10-pl/IQN17 crystal structure to 
the native post-fusion gp41 structure17 reveals that critical 
residues for binding in DIO-pl are very similar in chemical 
character to those of the natural C-peptide ligand (primarily 
W628, W631, and 1635), but adopt distinct conformations 
due to their opposite chirality.
Due to library diversity limitations, the first-generation 
library only surveyed about one in a million possible sequen­
ces.18 The identification of a strong EWXWL consensus 
sequence allowed us to fix these four residues to produce a 
“constrained” library with only six randomized residues 
(~ 1 0 9 possible sequences). Panning this library produced 
~  4-fold more potent inhibitors.79
Surprisingly, an 8-mer (CX8C) was also among the win­
ning sequences. Since 8-mers were not part of the library 
design and likely arose from rare replication errors, their rel­
ative success suggested that the 8-mer geometry might pro­
vide a better pocket-binding solution. Our crystal structure 
of the first identified 8-mer, PIE1 (pocket-specific inhibitor 
of entry), bound to IQN17 reveals that the key pocket-bind­
ing residues (WXWL) adopt nearly identical positions within 
the pocket as seen with DIO-pl, leading to very similar bind­
ing interfaces despite PIEl’s reduced length.79 The key differ­
ence between PIE1 and DIO-pl is a more compact D-peptide 
structure with a tighter hydrophobic core devoid of water. 
PIE1 has a D-Pro at position 8 that likely aids making the 
tighter turn necessary for circularization forced by the 
shorter disulfide-constrained loop.79
To completely explore 8-mer sequence space, a new library 
was generated with the core consensus sequence WXWL 
fixed (CX4WXWLC). While screening this library using tra­
ditional solid-phase phage display, we observed that polyva­
lency made it difficult to distinguish modest (flM) and tight 
(nM) binders. Solid-phase target presentation is advanta­
geous for selection of weak initial binders from a naive 
library, but problematic for identifying strong binders in a 
sea of modest binders since all binders are strongly retained 
on the high-density target surface. Moving the binding reac­
tion into solution (solution-phase phage display) reduces 
inter-target avidity and allows additional selection pressure 
by reducing target concentration through rounds of pan­
ning.80 Despite reduced inter-molecular avidity, solution- 
phase phage were still found to have dramatically higher 
binding affinities in the context of the panning than expected 
based on KD values of the derived D-peptides, likely due to 
intra-molecular avidity on the trimeric target. To overcome 
this barrier, an L-peptide version of PIE279 (identified during 
earlier rounds of solution-phase phage display) was 
employed as a soluble competitor for subsequent rounds of
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panning. Increased selection pressure was applied by escalat­
ing PIE2 concentrations, leading to the discovery of PIE7, 
which is ~  15-fold more potent than DIO-pl (IC50 =  620 
nM, HXB2 strain).
Our co-crystal structure of PIE7 in complex with IQN17 
suggested that further gains in binding affinity could be 
made through optimization of the residues outside the disul­
fide bond, which make significant gp41 contacts.79 Initially, 
these four “flanking” residues outside the disulfide bond 
(Gly-Ala on the N-terminus and Ala-Ala on the C-termi- 
nus) were not varied due to library cloning restrictions. We 
redesigned the phage display vector to relocate the cloning 
sites and allow randomization of the flank residues. After 
four rounds, PIE12 (HP-[PIE7 core]-EL) was identified with 
~  20-fold improved potency over PIE7. The PIE12/IQN17 
crystal structure (Figure 2) reveals that PIE12’s improved 
binding is likely due to ring-stacking interactions of D-Hisl 
and D-Pro2 with the pocket residue Trp571 and burial of an 
additional 50 A2 hydrophobic of surface area by D-Leul5.81 
Beyond the changes in the flanking regions, the central core 
structure is unchanged from PIE7.
Crosslinking and the Resistance Capacitor
After battling the confounding effects of avidity throughout 
our phage display screens, we hoped to re-introduce avidity 
to boost the potency of our D-peptides. Our D-peptide/N- 
trimer crystal structures reveal the precise relationship 
between neighboring D-peptides binding to the three symme­
try-related pockets. Using this information, we used discrete 
polyethylene glycol (PEG) crosslinkers to generate dimeric 
and trimeric D-peptides,79 which showed dramatically 
improved antiviral potency (up to 2000-fold) over mono­
meric D-peptides.79'81 PIE12-trimer, our lead inhibitor, is 
~  30-fold more potent than Fuzeon and inhibits a diverse 
panel of the most common circulating HIV strain subtypes 
worldwide in the high pM—low nM  range.81
Interestingly, we encountered a limit to the potency gains 
that could be achieved by monomer affinity optimization 
and crosslinking. We hypothesized that this potency plateau 
was imposed by the limited time window available for inhibi­
tor binding (target is only available in the transient pre-hair­
pin intermediate) and the inhibitor association rate (limited 
by diffusion), as previously observed for the pre-hairpin in­
termediate inhibitor 5-helix.82 Although this potency limit 
would prevent us from designing more potent inhibitors, we 
hypothesized that “over-engineering” our inhibitors (i.e., 
continuing to improve inhibitor binding despite a lack of 
corresponding improvement in potency) would endow them 
with a reserve of binding energy that would stall the develop­
ment of resistance mutations. We predict that this “resistance
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capacitor” would also greatly delay the emergence of resist­
ance by eliminating the selective advantage conferred by 
these mutations (i.e., severing the link between affinity and 
potency). Only a profoundly disruptive mutation would 
escape the resistance capacitor. In support of this hypothesis, 
we were only able to identify high-level PIE12-trimer resist­
ance after 65 weeks of viral passaging in the presence of in­
hibitor, compared with ~  3 weeks for Fuzeon.81 As predicted, 
PIE12-trimer was also able to absorb the impact of earlier- 
generation D-peptide resistance mutations.
PROTEASE-RESISTANT PEPTIDES FACE 
OTHER PHARMACOKINETIC CHALLENGES
Reduction of peptide susceptibility to proteases increases pep­
tide longevity, but another major threat to serum half-life is 
rapid clearance via renal filtration. For globular proteins, the 
glomerular filtration size limit is ~  70 kDa. Although albumin 
is slightly smaller, it avoids filtration because of electrostatic 
repulsion from the highly negatively charged glomerular base­
ment membrane. Albumin is the smallest major unfiltered 
protein, efficiently circulating in the bloodstream with a half­
life of approximately 19 days in humans.83 The small size of 
peptide therapeutics means that an additional level of design 
is required to reduce renal filtration and realize the full bene­
fits of protease resistance. Several common PK optimization 
strategies suitable for peptides are briefly described below.
PEG is a hydrophilic polymer commonly used for protein 
conjugation. Adding PEG to a protein has been one of the 
most clinically successful strategies for improving pharmaco­
kinetics.84 Early studies on the effects of PEG size on biodis­
tribution revealed that good serum retention is achieved 
between 40 and 60 kDa, while exceeding this range resulted 
in increased uptake and accumulation within the reticuloen­
dothelial system.85 Thus, the PEGylation field has largely 
adopted the strategy of adding ~  40 kDa of PEG weight to 
peptide and small protein therapeutics. PEG is extensively 
hydrated such that its hydrodynamic radius is much larger 
than expected from its molecular weight. Furthermore, dis­
tributing the weight of the PEG polymer in a branched ge­
ometry improves half-life and reduces steric interference.86 
PEG conjugation can also be reversible (e.g., an ester link­
age), creating a circulating depot from which the therapeutic 
is cleaved over time (e.g., in case drug activity is adversely 
affected by PEG conjugation).87'88 Limitations of PEGylation 
include steric interference with binding, long-lived accumu­
lation in renal tubule cells, viscosity, and polydispersity. An 
alternative approach uses a hydroxyethyl starch polymer 
(HESylation) to reduce renal filtration.89
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Albumin binding (covalent or noncovalent) is another 
recently validated approach for prolonging serum half-life 
(reviewed by Ref. 90). Promising albumin-binding strategies 
include covalent albumin-peptide conjugation, as well as re­
versible binding to circulating albumin via albumin-binding 
peptides, small molecules, or fatty acids.90-92 As an example, 
albumin conjugation of an HIV C-peptide inhibitor (either 
in vitro or in vivo) dramatically improves serum half-life,93 as 
does cholesterol conjugation to a lesser extent, presumably 
via weak reversible interactions with albumin and/or cell 
membranes.94
FUTURE DIRECTIONS
Recombinant Production of Peptidomimetics
Although robust recombinant production of peptidomimet­
ics is not yet possible, significant recent advances in synthetic 
biology may enable routine production of diverse peptidomi- 
metic libraries in the near future. One promising approach is 
in vitro codon reprogramming for the synthesis of unnatural 
polymers. This approach relies on cell-free translation sys­
tems to reconstitute ribosomal peptide synthesis using a 
minimal set of purified protein components. -  By chemi­
cally or enzymatically charging tRNA molecules with novel 
amino acid analogues, the genetic code can be effectively 
reprogrammed in vitro. When these cell-free systems with 
genetic code modifications are used in conjunction with a 
display technology, peptides with novel amino acids can be 
screened for a desired property. For example, ribosome dis­
play was used in conjunction with in vitro codon reprogram­
ming to isolate peptide sequences from an mRNA library 
that encoded an unnatural, selectable amino acid.101-103
Along these lines, it has been demonstrated that tRNAs 
can be charged with a variety of amino acid analogues that 
will modify the peptide backbone, including a-hydroxy acids, 
N-methyl amino acids, o,a-disubstituted amino acids, 
/5-amino acids, and D-amino acids.104 However, the efficiency 
of ribosomal incorporation of Ala/Phe analogues varies 
greatly from fairly robust (a-hydroxy acid and N-methyl) to 
weak (a,a-disubstituted amino acids) to undetectable (/?- and 
D-amino acids).104 Subsequent work has described the ability 
of the translation machinery to accommodate amino acid 
analogues with novel side chains and backbones.105
In one example, seven codons were each reassigned to 
encode a unique a-hydroxy acid, and polymers as long as 12 
consecutive a-hydroxy acids could be synthesized.106 In 
another report, the incorporation efficiencies of 23 N-methyl 
amino acids, 19 of which bore naturally occurring side
chains, were determined. Eight of these 19 N-methyl amino 
acids were incorporated at specific points in a polypeptide 
with >30% efficiency as compared with wild type. A peptide 
up to 10 residues long could be synthesized from three 
unique N-methyl amino acids.107
While less success has been reported with ribosomal 
incorporation of D-amino acids, modifications to the ribo­
somal peptidyltransferase center and helix 89 of the 23S 
rRNA can relax the ribosome’s natural substrate specificity, 
thereby enhancing the incorporation of D-amino acid resi­
dues into a growing polypeptide chain.108,109 Although these 
techniques have not yet been employed as such, in principle 
cell-free translation systems coupled with in vitro display 
techniques could be used to screen libraries of polymers with 
novel backbones. As an advance in this direction, genetic 
code reprogramming has already been used in conjunction 
with mRNA display technology to generate mRNA-peptide 
fusions containing N-methyl amino acids.110
Another approach to recombinantly produce peptidomi­
metics relies on the ability to expand the genetic code in vivo 
via the generation of evolved tRNA/aminoacyl-tRNA synthe­
tase pairs. In these systems, the foreign tRNA functions as an 
amber suppressor, effectively allowing the amber nonsense 
codon to be reprogrammed to encode a non-natural amino 
acid.111,112 It has been demonstrated that genetic code expan­
sion can be used in conjunction with phage display to incor­
porate a non-natural amino acid into a pill fusion pep­
tide.113 In the future, multiple codons could be reassigned, 
permitting the incorporation of multiple unnatural residues 
in vivo. Several advances have been made toward this end. In 
a recent publication describing a technique for rapid, ge­
nome-wide engineering, the authors show progress toward 
replacing all 314 TAG stop codons in E. coli with the TAA 
stop codon.114 This type of genome manipulation could be 
used for the removal of redundancy from the genetic code, 
freeing up codons for potential reprogramming. In another 
approach involving evolved tRNA/aminoacyl-tRNA synthe­
tase pairs, an evolved orthogonal ribosome able to read both 
3- and 4-base codons was able to efficiently incorporate two 
different non-natural amino acids into a single polypeptide 
chain in vivo.113,116 These approaches present tantalizing pos­
sibilities for the production of peptide libraries with unnatu­
ral side chains and backbones, but the technology is not yet 
sufficiently robust to allow for widespread application. Addi­
tional engineering of tRNA molecules, elongation factors, 
and the ribosome itself will likely be required for use with 
certain diverse peptidomimetics.109,117,118
D-Peptides present a unique opportunity for designing an 
artificial recombinant production system. Because o f their 
symmetry relationship with natural peptides, an in vitro
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translation system composed of all opposite-chirality compo­
nents (D-proteins and nucleotides containing L-ribose) would 
function equivalently to natural translation, when provided 
with mirror-image DNA substrates. Synthesis of all ribo- 
somal components presents an enormous synthetic chal­
lenge, but recent advances in SPPS and peptide ligation may 
now make this approach feasible. A mirror-image in vitro 
translation system would provide a useful tool for D-peptide 
drug discovery and production, but may not be ideal for 
large-scale production, especially of complex D-proteins (e.g., 
those requiring chaperones or post-translational modifica­
tions). The ultimate goal is to produce D-peptides using a 
synthetic mirror-image organism, a strategy we dub the “D. 
coli” project. The key to this project is synthesizing the mini­
mal set of RNAs and proteins necessary to allow enzymatic 
production of other larger components and ultimately all 
components needed for a self-replicating organism. It is also 
not yet clear how to “start up” such an organism.119’120
Cost and Toxicity of Peptidomimetics
In addition to achieving their biological objectives, peptido­
mimetics will need to overcome concerns about cost and tox­
icity to succeed as therapeutics. Currently there are no FDA- 
approved fully peptidomimetic peptides, so information on 
their in vivo toxicity is extremely limited. Initial data from 
two D-peptides that have advanced to clinical trials (Gen- 
zyme’s Delmitide121 and Allelix’s ALX40-4C122) showed that 
both D-peptides (one orally administered, one systemically 
delivered) were well tolerated in humans. Further comfort is 
provided by over a dozen approved D-amino acid-containing 
peptides, as well as two approved fi-amino acid-containing 
peptides.123 These data suggest that these amino acids are 
not intrinsically toxic, but more rigorous animal toxicology 
studies on different classes of fully protease-resistant peptides 
will be required for a definitive determination. Such studies 
will also determine whether these peptidomimetics induce 
significant immunogenicity upon chronic administration. 
Finally, the cost of D-, /?-, and other uncommon amino acids 
is currently significantly higher than the corresponding com­
mon L-amino acids, largely because of their current status as 
specialty reagents. However, we anticipate the cost of these 
amino acids will drop dramatically as they are adopted in 
high-volume production of therapeutic peptides, as has al­
ready occurred with several D-amino acids in large-scale pep­
tide production.
The authors thank Debra Eckert for critical review of the article and 
figures preparation. M.S.K. is a Scientific Director and consultant of 
the D-peptide Research Division of Navigen, which is commercializ­
ing D-peptide inhibitors of viral entry.
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CHAPTER 6
CONCLUSIONS AND FUTURE DIRECTIONS
Conclusions
Significant progress has been made in the last three decades in the development of 
HIV therapeutics, with resulting dramatic decreases in the AIDS mortality rate. Despite 
these successes, there remains a public health need for new HIV inhibitors to improve 
current therapy, provide treatment to patients harboring multidrug resistant virus, and 
develop an economical option for treatment and prevention in developing nations.
Cholesterol-PIE12-trimer is a D-peptide inhibitor of HIV entry with mid-pM 
potency against the difficult-to-inhibit primary strain JRFL1. Cholesterol-PIE12-trimer 
builds upon previously developed D-peptides, with improvements in both potency and 
pharmacokinetics that make this compound a promising lead in the field of entry 
inhibitors. Moreover, this work illustrates the promise of D-peptides as therapeutics, and 
provides the groundwork for application of this technology to other viruses as well as 
disrupting protein-protein interactions in general. Protein-protein interactions remain one 
of the most challenging problems in drug development due to the need for very high 
specificity and generally large interaction surfaces. Peptides offer the ability to overcome 
this barrier, and D-peptides have all of the advantages of L-peptides without the
proteolytic degradation. Future development of D-peptide inhibitors of HIV entry will 
provide critical information regarding the in vivo properties of D-peptides.
The excellent potency of cholesterol-PIE12-trimer, together with the advantages 
of D-peptides, makes this inhibitor an excellent microbicide candidate. Microbicides 
offer the potential for economical and effective agents to prevent HIV infection, and 
could provide a mechanism to dramatically reduce the incidence of new infections 
worldwide. The environment of the vaginal and rectal mucosa is extremely protease-rich, 
making protease-resistant D-peptides ideal microbicide candidates. Moreover, D- 
peptides exhibit excellent stability, critical for use in developing nations that may lack the 
infrastructure to maintain temperature control from production to clinic.
Future Directions 
PBMC Infectivity Assays 
Much of the in vitro work examining the efficacy of D-peptides to date has been 
performed in cell lines using single cycle HIV-1 pseudovirions. This system is 
advantageous for its simplicity, allowing for very consistent results across many 
generations of work and the safety of non-replicative virus. However, the cell lines tested 
differ from the natural target cells of HIV in expression levels of receptor and coreceptor, 
which can alter fusion kinetics. Additionally, pseudotyped virions can differ in the 
efficiency of Env processing and incorporation.
Performing infectivity assays in peripheral blood mononuclear cells (PBMCs) 
allows for wild-type receptor and coreceptor levels. Together with the use of replication- 
competent virus, this assay mimics in vivo infection as closely as possible. In addition,
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efficacy against a broad panel of isolates representing all major circulating strains will be 
performed to evaluate cholesterol-PIE12-trimer.
Resistance to D-Peptide Inhibitors 
Ongoing viral passaging studies with the Root Lab (TJU) have identified several 
PIE12-trimer resistance mutations, notably Q577R and E560K/V570I2. The same assay 
has recently been started both from wild-type and PIE12-trimer resistant virus using 
cholesterol-PIE12-trimer to determine which mutations arise, and if the route to 
resistance is similar to that of PIE12-trimer. To analyze the resistant pools better we have 
adopted a deep-sequencing method that allows for rapid analysis of polyclonal pools with 
high fidelity3. Once resistance is obtained against cholesterol-PIE12-trimer, the resistant 
pools will be sequenced to determine which mutations arise, and observed mutations will 
be cloned for detailed analysis of the resistance mechanism.
Resistance often comes at the cost of viral fitness. One such cost is a reduced 
viral Env incorporation4 or a change in the stability of the gp120-gp41 interface, leading 
to shedding of gp1205. Env incorporation in JRFL pseudovirions as well as replication 
competent JRFL will be examined to determine if these mutations lead to a decrease in 
Env incorporation or stability. To examine the fitness cost for these mutations further, 
competition growth assays will be performed with both wild type and resistant 
replication-competent viruses. Additionally, clonal resistant virus will be grown in the 
absence of inhibitor to determine if the virus reverts to wild-type in the absence of 
selection pressure, a strong indication that the observed mutations confer a growth 
disadvantage.
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Resistance mutations to entry inhibitors that target the pocket can be broadly 
defined to function either through changing the binding affinity of the inhibitor, or 
altering the kinetics of fusion. To determine if the kinetics of fusion are altered, 
inhibition assays will be carried out using cell lines with altered levels of receptor and 
coreceptor that speed or slow fusion6. Cholesterol conjugates are believed to localize to 
the site of entry, reducing the kinetic barrier by decreasing the volume that the inhibitor 
must search to find its target. Changes in fusion kinetics should affect the potency of the 
cholesterol-conjugated inhibitors comparably to PIE12-trimer, as both inhibitors are 
kinetically limited (though cholesterol conjugation reduces the kinetic barrier).
Preclinical Development
PIE12-trimer and cholesterol-PIE12-trimer will be examined for efficacy in a 
non-human primate model against SIV and/or SHIV in conjunction with detailed 
pharmacokinetic analysis in this animal model. These inhibitors will be examined both 
for the ability to suppress viral load in a systemic infection as well as in a vaginal or 
rectal challenge as a microbicide. In the short term, D-peptides will be examined in 
cervical and rectal explant assays to test efficacy, tissue penetration, and toxicity. In 
parallel, formulation studies will be undertaken, with the ultimate goal of weekly or 
monthly dosing for systemic therapy and monthly vaginal ring formulation.
In the pathway to IND, and ultimately clinical approval, several challenges 
remain for D-peptide therapeutics. The safety of D-peptides for long-term use remains 
unknown, though toxicity studies underway suggest that there is nothing inherently toxic 
about D-peptides. However, since D-peptides are resistant to proteolysis, the possibility
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of accumulation within the body remains an open question. However, the scaffold design 
allows for incorporation of degradable bonds to promote degradation and renal clearance. 
Future work will include long-term toxicity studies to carefully examine for this 
possibility. We are very interested in understanding if cholesterol conjugation localizes 
D-peptide inhibitors to a specific compartment such as the liver. To test for this 
possibility, detailed pathology and histology will be performed, and we plan to perform 
fluorescence localization studies on live animals to track the fate of our inhibitors using 
fluor-conjugated inhibitors. PK analysis will be performed in parallel to verify that fluor 
conjugation does not significantly alter D-peptide pharmacokinetics.
It is also unknown if it is possible to mount a robust immune response to D- 
peptides. Peptide proteolysis is required for processing and presentation of antigens by 
the major histocompatability complex (MHC). Since D-peptides are protease resistant, it 
is believed that they will be less immunogenic than L-peptides, but this question will not 
have a definitive answer until animal immunogenicity and clinical studies are performed.
D-peptides are uniquely advantageous for microbicide application, but significant 
work remains in the pathway to clinical application. Development of a microbicide 
necessitates a better understanding of how effectively D-peptides penetrate and persist in 
local tissue. Protease insensitivity may allow for lower and less frequent dosing if D- 
peptides are able to penetrate into tissue and accumulate, allowing for reduced cost.
The hairpin closure entry mechanism utilized by HIV is utilized by a number of 
viruses, including influenza, ebola, and respiratory syncytial virus (RSV). At this time, 
no effective therapy is available for ebola, and only one preventative agent (Synagis) is
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available for RSV. Using the mirror-image phage display process optimized for HIV, we 
are working towards discovering D-peptide inhibitors of entry for these viruses.
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